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A B S T R A C T
Background
Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being
developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels),
which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy
regimens improves survival, and what the side-effects may be.
Objectives
To compare the effectiveness and toxicities of angiogenesis inhibitors in the treatment of ovarian cancer.
Search methods
We sought to identify completed randomised controlled trials (RCTs) by searching The Cochrane Gynaecological Cancer Review
Group’s Trial Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10),
MEDLINE and EMBASE (1990 toOctober 2010). We also searched registers of clinical trials, and contacted investigators of completed
and ongoing trials for further information.
Selection criteria
Randomised controlled studies comparing angiogenesis inhibitors with either standard chemotherapy or no treatment, in women with
ovarian cancer.
Data collection and analysis
Two independent authors carried out data collection and extraction. We used a random-effects model for pooling data.
Main results
We did not find any fully-published, completed RCTs of angiogenesis inhibitors that met our inclusion criteria. We identified five
abstracts of completed RCTs of four different angiogenesis-inhibiting agents, with a total of 3701 participants.
Meta-analysis of two trials found no statistically significant difference in overall survival (OS) between women with newly-diagnosed
advanced ovarian cancer who received concurrent and maintenance bevacizumab compared to those who received chemotherapy
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(carboplatin and paclitaxel) alone. However, women who received concurrent and maintenance bevacizumab had their risk of disease
progression reduced by a quarter (hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.68 to 0.83; P < 0.001); they also had a
significantly increased risk of severe gastrointestinal adverse events, moderate or severe hypertension and severe bleeding.
One trial also compared chemotherapy to concurrent (but not maintenance bevacizumab), and found no statistically significant
difference in OS or progression-free survival (PFS). However, the women who received bevacizumab had a significantly higher risk of
moderate or severe hypertension.
A three-armed RCT, of paclitaxel alone or with low- or high-dose AMG 386, in women with recurrent ovarian cancer, found no
statistically significant difference in OS. However, women who received low-dose AMG 386 had a third less risk of disease progression
than those who received placebo (HR 0.57, 95% CI 0.36 to 0.91; P = 0.02). The trial found no evidence of increased adverse events
in the intervention arms.
Two relatively small RCTs (one of VEGF-Trap, the other of BIBF 1120) found no evidence of either significant survival benefit or
increased severe adverse events, compared to placebo, but they both lacked statistical power.
All five trials had unclear risk of bias, largely because they have only been published in abstract form, and thus many methodological
details are unclear. We identified twelve suitable ongoing trials.
Authors’ conclusions
There is, as yet, no fully-published RCT evidence for the efficacy or safety of angiogenesis inhibitors for the treatment of ovarian cancer,
but some preliminary results are available from five trials. There is some evidence from a meta-analysis of two trials that the addition
of concurrent and maintenance bevacizumab to standard chemotherapy may reduce the risk of disease progression, in women with
newly-diagnosed advanced ovarian cancer. There is also some evidence from a single trial that low-dose AMG 386 may reduce the risk
of disease progression in women with recurrent ovarian cancer. However, there is currently no evidence that angiogenesis inhibitors
improve OS, nor is there enough evidence to justify the routine use of angiogenesis inhibitors in treating women with ovarian cancer.
We eagerly await both the more detailed results of these five completed trials, and the preliminary results of the several ongoing trials.
P L A I N L A N G U A G E S U M M A R Y
Are substances that inhibit the growth of new blood vessels (angiogenesis inhibitors), alone or in combination with conventional
chemotherapy, likely to improve outcomes for women with ovarian cancer?
Ovarian cancer is the seventh most common cancer in women worldwide, with an annual incidence of about 6.3 cases per 100,000
women, and an annual mortality rate of 3.8 per 100,000 women. Standard treatment of advanced ovarian cancer usually involves
surgery, to remove as much of the cancer as possible (’debulking’), and platinum-based chemotherapy, with or without the addition
of a taxane. However, despite good initial responses to platinum agents and taxanes, most women have disease relapse, require further
treatment with chemotherapy, and eventually develop resistance to conventional chemotherapy drugs.
Many researchers are trying to find new drugs, which target different pathways, in order to treat ovarian cancer that has become resistant
to standard chemotherapy. One target is the pathway for angiogenesis: the growth of new blood vessels. Although new blood vessels
can form as part of the body’s normal processes, cancers are especially reliant on angiogenesis, as they need a blood supply in order to
grow. It is hoped that drugs that act to inhibit the growth of new blood vessels will slow or stop the progression of the cancer.
In this review we found evidence from five studies, comparing drugs which inhibit angiogenesis against either standard chemotherapy
(carboplatin + paclitaxel) or placebo.
Two trials looked at the effect of adding bevacizumab to conventional chemotherapy in women who had just been diagnosed with
ovarian cancer and had debulking surgery. Bevacizumab was given both alongside the chemotherapy, and then continued afterwards
(called maintenance therapy). Taking the results of these two trials together, there was no significant benefit from adding bevacizumab
to standard chemotherapy in terms of survival time, but there was fairly strong evidence that it might slow the growth of the cancer
(increased progression-free survival (PFS)). However, the trials also showed that there were worse side effects in women who received
bevacizumab in addition to chemotherapy (particularly high blood pressure, serious bowel problems and bleeding). One of these two
trials also looked at the effect of giving bevacizumab concurrently with chemotherapy (not continuing afterwards), and found no
significant improvement in either survival time or slowing cancer growth, but did find a significant increase in moderate and severe
high blood pressure (hypertension).
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A third trial looked at adding a different agent, AMG 386, to paclitaxel chemotherapy in women with recurrent ovarian cancer. The
trial compared the addition of either a higher or lower dose of AMG 386 to placebo. It found no improvement in survival with either
the higher or lower dose of AMG 386, but there were suggestions that it might slow cancer growth. It did not seem to increase side
effects.
We identified two other trials; one comparing placebo to BIBF 1120, and the other comparing placebo to VEGF (vascular endothelial
growth factor)-Trap. Neither study found evidence of slowing cancer growth/prolonging survival, or worsening side effects. However,
these were both relatively small studies, which made them less likely to detect an effect that may or may not have been present.
All of the included trials that we identified reported only preliminary results, which had been presented at conferences, but not yet
published in full. It is thus difficult to be sure of the specific details of how these trials were performed, and therefore to assess their risk
of bias. We found 12 other on-going studies that fulfilled our inclusion criteria, and some of these are expected to release preliminary
results soon.
B A C K G R O U N D
Description of the condition
Each year, worldwide, nearly 225,000 women are diagnosed with
ovarian cancer and over 140,000 die, corresponding to an annual
age-standardised incidence of 6.3 cases per 100,000 women, an
annual mortality rate of 3.8 deaths per 100,000, and a cumulative
lifetime risk of 0.68% (GLOBOCAN 2008). In terms of both
incidence and mortality, it is the seventh most common cancer in
women. The onset is often insidious; the symptoms are vague and
maymimic other conditions. Thismay lead to a delay in diagnosis,
and currently three-quarters of women with ovarian cancer are
diagnosed when the disease has spread throughout the abdomen
(stage III or IV) (Shepherd 1989) when the five-year survival rate
is 20% to 30% (Jemal 2008). Epithelial ovarian cancer, which
arises from the surface of the ovary, accounts for 90% of all ovarian
cancers and typically presents in post-menopausal women, with
a peak incidence when women are in their early sixties, although
it does occur in younger women, often associated with genetic
predispositions (Quinn 2001).
Description of the intervention
Management of advanced ovarian cancer consists of debulking
surgery, and platinum-based chemotherapy, with or without the
addition of a taxane (Morrison 2007; Stewart 1999). A recent
RCT found that there was no difference in survival, if surgery was
performed before or after the first three cycles of chemotherapy
(Vergote 2010). However, in women presenting with advanced
disease, there has been little change to the five-year survival rate
for stage III to IV of the disease over the past 20 to 30 years
(Engel 2002). Despite good initial response to platinum agents
and taxanes, most women have disease relapse, require further
treatment with chemotherapy, and eventually develop resistance
to conventional chemotherapeutic agents.
Conventional chemotherapeutic agents have activity on all rapidly
dividing cells, hence the common side effects such as: hair loss;
bone marrow suppression; and mucositis (inflammation and ul-
ceration of the mucous membranes lining the digestive tract). In-
creasing knowledge of the genetic basis for cancer has lead to the
development of novel reagents, which target cancer-specific path-
ways. It is hoped that these reagents will spare normal cells and re-
duce the toxic side effects of chemotherapy, in addition to having
an enhanced therapeutic effect.
How the intervention might work
Angiogenesis and ovarian cancer
Angiogenesis is the development of new blood vessels. Once a tu-
mour deposit is larger than 1 mm in diameter it cannot receive
adequate nutrients or oxygen from surrounding tissues by diffu-
sion alone and it must then stimulate new blood vessel formation
to support further growth. Angiogenesis is a vital part of embryo
development, but is tightly controlled in adults and normally oc-
curs during wound healing and as part of ovulation. Abnormal
angiogenesis can occur in a variety of illnesses, either stimulated by
low oxygen levels in tissues, e.g. diabetes and metastatic cancer, or
in inflammatory conditions, such as rheumatoid arthritis (Fidler
1994; Folkman 1990). In contrast to the ordered formation of
new blood vessels during embryonic angiogenesis, tumour angio-
genesis is disordered and results in abnormal and leaky blood ves-
sels (McDonald 2002). Blocking this process may prevent growth
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of small tumour deposits and improve survival of patients with
cancer.
Angiogenesis requires signalling between tumour cells and nearby
endothelial (lining) cells of normal blood vessels, stimulating them
to sprout, multiply and invade the growing tumour. The process
involves release of agents by cancer cells, stimulated by low oxy-
gen levels or low pH. These agents bind to receptors on endothe-
lial cells, which then trigger downstream intracellular signalling,
leading to growth and migration of endothelial cells. This process
can be inhibited at each of these stages. Because angiogenesis is
normally inactive in adults, its inhibition is an attractive candidate
for selective anti-tumour therapies. Another advantage is that tu-
mour endothelial cells are not themselves malignant and so, un-
like cancer cells themselves, do not have pre-existing mutations
that favour the development of further mutations, which could
lead to drug resistance. In addition, anti-angiogenic agents may
work synergistically with conventional chemotherapeutic agents
or other novel systemic agents, due to their different mechanisms
of action.
Vascular endothelial growth factor (VEGF) is one of the key el-
ements in the stimulation of angiogenesis. VEGF is released by
cancer cells and binds to a receptor on endothelial cells (VEGF-R)
(Figure 1 A-B). VEGF binding stimulates tyrosine kinase activity
in theVEGF-R (Figure 1 B), which in turn stimulates downstream
signalling and activation of endothelial cells (Figure 1 C). VEGF
over-expression is associated with ascites formation (build up of
fluid within the abdominal cavity) and poorer prognosis (Oehler
2000).
Figure 1. (A) The VEGF-R is a transmembrane protein, found on cells, which line blood vessels (endothelial
cells). (B) Following binding to its ligand, VEGF, the VEGF-R is stimulated and develops tyrosine kinase activity.
(C) Tyrosine kinase activity sets off a sequence of downstream events that lead to stimulation of cell growth
and new vessels grow in, to supply the growing tumour. (D) VEGF-R activity can be blocked by antibodies,
which bind to VEGF, and so stop it binding to the receptor, or using chemicals, which inhibit the tyrosine
kinase enzyme activity of the VEGF-R.
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VEGF signalling can be blocked at several levels (Figure 1 D).
First, anti-VEGF antibodies or soluble VEGF-R molecules mop
up excess VEGF and prevent binding to, and stimulation of, cel-
lular VEGF-R. Second, antibodies have been developed that bind
to VEGF-R and block binding and activation by VEGF. Third,
VEGF-R signalling may also be inhibited by small molecules
which specifically inhibit the intracellular tyrosine kinase activity
of VEGF-R following stimulation by angiogenic factors.
VEGF-R tyrosine kinase inhibitors
Small molecule inhibitors of VEGF-R tyrosine kinase have been
developed and investigated in clinical trials. One advantage of
these compounds is that many are orally active.
AZD2171 (cediranib or RecentinT M Astra Zeneca) is a small
molecule inhibitor of VEGF-R that has demonstrated benefit in
preclinical studies (Wedge 2005). Phase II studies have also shown
that AZD2171 is an active drug in patients with recurrent ovarian
cancer (Hirte 2008; Matulonis 2008). The most frequent side ef-
fects were tiredness, diarrhoea, hypertension and anorexia. A large
multicentre phase III study (ICON6: NCT00532194) is evalu-
ating the role of AZD2171 in patients with recurrent platinum-
sensitive ovarian cancer.
Pazopanib is a potent selective receptor tyrosine kinase inhibitor
of VEGF-R, PDGF-R (platelet derived growth factor receptor)
and c-kit that blocks tumour growth and inhibits angiogenesis.
It has shown biological activity in patients with CA125-positive
recurrent ovarian cancer after primary platinum-based therapy (
Friedlander 2010).
BIBF 1120 is an oral, small molecule, triple angiokinase inhibitor,
targeting VEGF-R, FGF-R (fibroblast growth factor receptor) and
PDGF-R. A recent phase II study has evaluated its use in main-
tenance of post-relapse remission in patients who responded to
second, third or fourth line chemotherapy (Ledermann 2009).
Sorafenib [N-(3-trifluoromethyl-4-chlorophenyl)-N’-(4-(2-
mehtylcarbamoyl pyridin-4-yl) oxyphenyl) urea; BAY 43-9006/
Nexavar] is a tyrosine kinase inhibitor that directly inhibits VEGF-
R in addition to other angiogenic and growth stimulatory path-
ways (via Raf kinase inhibition) (Mross 2007; Siu 2006). Activity
has been demonstrated against ovarian cancer in early clinical tri-
als for pre-treated relapsed disease (Siu 2006) and its role in first-
line treatment for ovarian cancer is under evaluation (Hainsworth
2010).
Sunitinib (SU11248) is a VEGF-R tyrosine kinase inhibitor and
is being tested for activity in women with relapsed ovarian cancer
in a non-randomised, non-blinded, multicentre phase II trial (
Buckstein 2007).
VEGF blockade
Monoclonal antibodies are antibodies that have a specific target
pattern to which they bind. Bevacizumab (Avastin) is a humanised
monoclonal antibody that binds VEGF, prevents it binding to
VEGF-R, and so inhibits VEGF-R activation. Bevacizumab has
been shown to have activity in phase II trials in women who had
platinum-resistant relapsed ovarian cancer (13% to 16% partial
response rates and 25% to 55% stable disease), although complete
responses, in this group of pre-treated patients, were low (0% to
5%) (Burger 2007; Cannistra 2007). Side effects encounteredwere
different to those seen with conventional chemotherapy, in line
with its alternative mode of action and included hypertension,
bleeding episodes, thromboembolism and bowel perforation.
On the basis of success from these studies, phase III trials have been
performed combining bevacizumab with carboplatin and taxol
chemotherapy in postoperative patients with ovarian cancer in the
GOG 218 (Burger 2010 (GOG-0218)) and the ICON 7 (Perren
2010 (ICON7)) study. These trials are also assessing the role of
bevacizumab in the maintenance treatment of these patients.
Why it is important to do this review
Novel treatment strategies working in different ways to conven-
tional chemotherapy have been developed. It is important to es-
tablish whether the addition of these new drugs to conventional
chemotherapy regimens has additional benefit, in terms of sur-
vival, and if so, at what cost, in terms of additional harmful effects.
Furthermore, since these compounds may be less toxic compared
to conventional chemotherapeutic agents, it may be possible to use
these newer treatments in patients who are not currently taking
chemotherapy (so called maintenance treatment), to reduce the
chance of, or delay, the recurrence of their ovarian cancer.
O B J E C T I V E S
To compare the effectiveness and toxicities of angiogenesis in-
hibitors in the treatment of ovarian cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of angiogenesis inhibitors
plus conventional chemotherapy versus conventional chemother-
apy alone, and angiogenesis inhibitors versus no treatment.
Types of participants
Adult women with histologically proven ovarian cancer. Women
with other concurrent malignancies were excluded.
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Types of interventions
• Angiogenesis inhibitors + conventional chemotherapy
versus conventional chemotherapy.
• Angiogenesis inhibitors versus no treatment.
Types of outcome measures
Primary outcomes
Overall survival (OS): survival until death from all causes.
Secondary outcomes
1. Progression-free survival (PFS).
2. Quality of life (QoL), measured by a validated scale.
3. Toxicity; grades of toxicity were extracted and grouped
(CTEP 2006) as follows:
◦ haematological (leucopenia, anaemia,
thrombocytopenia, neutropenia, haemorrhage);
◦ gastrointestinal (nausea, vomiting, anorexia, diarrhoea,
liver, proctitis);
◦ genitourinary;
◦ skin (stomatitis, mucositis, alopecia, allergy);
◦ neurological (peripheral and central); and
◦ other side effects not categorised above.
Search methods for identification of studies
We sought papers in all languages but no translations were neces-
sary.
Electronic searches
See: Cochrane Gynaecological Cancer Groupmethods used in re-
views.
We searched the following electronic databases.
• The Cochrane Gynaecological Cancer Review Group’s Trial
Register.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2010, Issue 10).
• MEDLINE up to October 2010.
• EMBASE up to October 2010.
The MEDLINE, EMBASE and CENTRAL search strategies
based on terms related to the review topic are presented in
Appendix 1, Appendix 2 and Appendix 3 respectively.
We searched databases from 1990 to October 2010. These novel
agents have been developed recently and so searches before 1990
would not have been relevant.
We had planned that all relevant articles found would have been
identified on PubMed and, using the ’related articles’ feature, we
would have carried out a further search for newly published arti-
cles. However, all included trials in this review have thus far only
been published in the form of conference abstracts, which were
not identifiable on PubMed.
Searching other resources
We
searched the Physicians Data Query, www.controlled-trials.com/
rct, www.clinicaltrials.gov, www.cancer.gov/clinicaltrials and the
National Research Register (NRR) for ongoing trials. We also
sought details of ongoing or unpublished trials from the
FDA (Food and Drug Administration, the regulatory body for
medicines within the USA, www.fda.gov) and EMEA (Euro-
pean Medicines Agency, the drug regulatory body within Europe,
www.emea.europa.eu) and frompharmaceutical company sources.
We contacted themain investigators of the relevant completed and
ongoing trials for further information.
As all included trials were reported in abstract form or data were
obtained from conference presentations or by contacting trialists,
we could not search reference lists of included trials for further
relevant trials as specified in the protocol.
Correspondence
We contacted authors of relevant trials to ask if they knew of
further data which may or may not have been published.
Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching to the referencemanagement databaseEndnote, removed
duplicates and two review authors (KG, IM) independently exam-
ined the remaining references. We excluded those studies which
clearly did not meet the inclusion criteria and obtained copies of
the full text of potentially relevant references. Two review authors
(KG, IM) independently assessed the eligibility of retrieved pa-
pers.. We resolved disagreements by discussion between the two
review authors and when necessary by a third review author (JM
or SN). We documented the reasons for exclusion.
Data extraction and management
For included studies, we extracted the following data.
• Author, year of publication and journal citation (including
language)
• Country
• Setting
• Inclusion and exclusion criteria
• Study design, methodology
• Study population
◦ Total number enrolled
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◦ Patient characteristics
◦ Age
◦ Co-morbidities
◦ Previous treatment
• Total study duration
• Total number of intervention groups
• Ovarian cancer details at diagnosis
◦ FIGO stage
◦ Histological cell type
◦ Tumour grade
◦ Extent of disease
• Intervention details
◦ Type of angiogenesis inhibitor
◦ Dose
◦ Duration of treatment
◦ Consolidation treatment or treatment of active disease
• Comparison details
◦ Type of control: conventional chemotherapy or no
treatment
◦ Dose (if appropriate)
◦ Duration (if appropriate)
• Deviations from protocol
• Risk of bias in study (see Assessment of risk of bias in
included studies below)
• Duration of follow-up
• Outcomes: OS, PFS, QoL, toxicity.
◦ For each outcome: outcome definition (with
diagnostic criteria if relevant).
◦ Unit of measurement (if relevant).
◦ For scales: upper and lower limits, and whether high
or low score is good.
◦ Results: number of participants allocated to each
intervention group.
◦ For each outcome of interest: sample size; missing
participants.
We extracted data on outcomes as follows.
• For time-to-event data (OS and PFS) we extracted the log of
the HR [log(HR)] and its standard error (SE) from trial reports.
If these were not reported, we attempted to estimate them from
other reported statistics using the methods of Parmar 1998.
• For dichotomous outcomes (e.g. toxicity), we extracted the
number of patients in each treatment arm who experienced the
outcome of interest and the number of patients assessed at
endpoint, in order to estimate a risk ratio (RR).
When reported, we extracted both unadjusted and adjusted statis-
tics.Where we extracted adjusted results, we recorded the variables
that were adjusted for.
Where possible, all data that we extracted were those relevant to
an intention-to-treat (ITT) analysis, in which participants were
analysed in groups to which they were assigned.
We noted the time points at which outcomes were collected and
reported.
Two review authors (KG and JM, rather than KG and IM, as in
the protocol) extracted data onto a data extraction form specially
designed for the review. The review authors resolved differences
by discussion or by appeal to a third review author (IM or SN)
when necessary.
Assessment of risk of bias in included studies
We assessed the risk of bias in included RCTs using the Cochrane
Collaboration’s tool. This included assessment of the following.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data: we recorded the proportion of
participants whose outcomes were not reported at the end of the
study; we noted whether loss to follow-up was not reported. We
coded a satisfactory level of loss to follow-up for each outcome as:
◦ ’low risk’, if fewer than 20% of patients were lost to
follow-up and reasons for loss to follow-up were similar in both
treatment arms;
◦ ’high risk’, if more than 20% of patients were lost to
follow-up or reasons for loss to follow-up differed between
treatment arms; and
◦ ’unclear risk’ if loss to follow-up was not reported.
• Selective reporting of outcomes.
• Other possible sources of bias.
Two review authors (JM, KG) independently applied the risk of
bias tool and resolved differences by discussion or by appeal to a
third review author (SK orHD).We have presented results in both
a risk of bias graph and a risk of bias summary. We interpreted the
results of meta-analyses in light of the findings with respect to risk
of bias.
Measures of treatment effect
We used the following measures of the effect of treatment.
• For time-to-event data, we used the HR.
• For dichotomous outcomes, we used the RR.
If adjusted results were available, they were preferred; otherwise
we used unadjusted results.
Dealing with missing data
We did not impute missing outcome data for any of the outcomes.
Assessment of heterogeneity
We assessed heterogeneity between studies by visual inspection of
forest plots, by estimation of the percentage heterogeneity between
trials which cannot be ascribed to sampling variation (Higgins
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2003) and by a formal statistical test of the significance of the
heterogeneity (Deeks 2001). If there was evidence of substantial
heterogeneity, we investigated and reported the possible reasons
for this.
Data synthesis
If sufficient, clinically similar trials were available, we pooled their
results in meta-analyses.
• For time-to-event data, we pooled HRs using the generic
inverse variance facility of RevMan 5.
• For any dichotomous outcomes, we calculated the RR for
each study and then pooled these.
We used random-effects models with inverse variance weighting
for all meta-analyses (DerSimonian 1986).
The Burger 2010 (GOG-0218) trial had multiple treatment
groups (three-arm trial), and so we divided the control group be-
tween the treatment groups, and treated comparisons between
each treatment group and a split control group as independent
comparisons for all adverse event outcomes. This was not neces-
sary for OS as we obtained HR estimates from a Cox regression
model.
Subgroup analysis and investigation of heterogeneity
As we expected to find few trials, we did not plan any subgroup
analyses. However, in the interpretation of heterogeneity we con-
sidered factors such as type of intervention (e.g. use as early stage
consolidation therapy in chemo-sensitive cancers or use in late
stage chemo-resistant cancers) and stage of disease.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
From the main search strategy we found 4248 unique references
(after we had removed most duplicates); two review authors (IM
and KG) independently examined these abstracts. We identified
14 studies as potentially eligible for this review from the title and
abstract screening of these references. We excluded seven of these
studies after obtaining the full text, for the reasons described in
the Excluded studies section. Four of the references were confer-
ence abstracts that described RCTs that fulfilled our criteria. Three
of these were studies that had completed primary data collection
(Burger 2010 (GOG-0218);Karlan 2010; Ledermann 2009).One
study was still ongoing at the time of finding the most recent
abstract using our search strategy (Mazur 2006, subsidiary refer-
ence to Perren 2010 (ICON7)); however, further handsearching
and contacting of investigators identified that results had recently
been reported at a conference (Perren 2010 (ICON7)). Through
searching clinical trial databases we identified a fifth completed
RCT; we contacted the investigators who revealed that this had
been presented and published as a conference abstract (Vergote
2009), and will be published in full shortly. Three references were
to ongoing trials, two of which should be suitable for inclusion
when completed (Hainsworth 2010; McGuire 2010), and one of
which is awaiting classification (Gordon 2010).
We searched clinical trial databases for ongoing studies and iden-
tified 10 further ongoing RCTs that should be suitable for inclu-
sion when completed (some of these studies have now completed
early outcomes, and will publish preliminary results shortly, e.g.
OCEANS: NCT00434642). We identified another six ongoing
trials which we considered for inclusion, but then excluded for the
reasons described in the Excluded studies section.
Included studies
We included five RCTs published in abstract form (Burger
2010 (GOG-0218); Karlan 2010; Ledermann 2009; Perren 2010
(ICON7); Vergote 2009) (with results reported at recent confer-
ences), as they met the inclusion criteria.
Burger 2010 (GOG-0218) was a randomised, double-blind,
placebo-controlled, phase III study of bevacizumab in 1873
women with newly-diagnosed epithelial ovarian cancer, primary
peritoneal cancer or fallopian tube cancer. All women were within
1 to 12 weeks of initial debulking surgery, and had stage III-
IV disease, with a Gynecologic Oncology Group (GOG) perfor-
mance status of zero to two. It was a three-armed study, compar-
ing chemotherapy (carboplatin and paclitaxel) plus placebo (arm
one = 625 women), versus chemotherapy plus concurrent beva-
cizumab (arm two = 625 women), versus chemotherapy plus con-
current and maintenance bevacizumab (arm three = 623 women).
All women received paclitaxel 175 mg/m2 + carboplatin AUC 6
(AUC = area under the curve) for cycles one to six; women in
arm one also received placebo for cycles 2 to 22; women in arm
two received bevacizumab 15 mg/kg concurrently with the che-
motherapy for cycles two to six, and then placebo for cycles 7
to22; women in arm three received concurrent bevacizumab for
cycles two to six, and then maintenance bevacizumab for cycles
7 to 22. The median age in each arm was 60 years. Six hundred
and thirty-nine (34%) patients had stage III disease with optimal
surgical cytoreduction; 752 (40%) patients had stage III with sub-
optimal cytoreduction and 482 (26%) had stage IV disease. The
primary outcome was PFS; secondary outcomes included OS, sa-
fety, QoL and correlative laboratory studies. Preliminary results
for PFS, OS and adverse events have been published in conference
abstracts and presentations (events had been observed in 24% of
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patients at time of data lock). The median length of follow-up (for
reported data thus far) was 17.4 months (range 0.0-50.7 months).
Randomisation (and hence also analysis) was stratified by GOG
performance status and by stage/debulking status.
Perren 2010 (ICON7) was a randomised, open-label, phase III
study of bevacizumab (given both concurrently with chemother-
apy, and then as maintenance therapy), versus chemotherapy
alone, in 1528 women with newly-diagnosed epithelial ovarian
cancer, primary peritoneal cancer or fallopian tube cancer.Women
in both study arms received carboplatin AUC6 and paclitaxel 175
mg/m2 once every three weeks for up to six cycles; those in the
intervention arm additionally received bevacizumab 7.5 mg/kg
once every three weeks, for up to a total of 18 cycles (six cycles
with chemotherapy, plus a further 12 cycles). One thousand three
hundred and forty (88%) women had epithelial ovarian cancer, 56
(3%) had fallopian tube cancer, 106 (7%) had primary peritoneal
cancer and 26 (2%) women had cancer at multiple sites. One hun-
dred and forty-two (9%) women had FIGO stage I/IIA disease,
315 (21%) had stage IIB to IIIB and 1071 (70%) had stage IIIC/
IV disease. The median age was 57 years in both groups. The pri-
mary outcome was PFS, defined by Response Evaluation Criteria
In Solid Tumors (RECIST) guidelines on radiological, clinical or
symptomatic progression. Secondary outcomes included OS, re-
sponse rate, duration of response and toxicity (with sub-studies
planned on QoL, health economics and translation/biomarker re-
search). The median length of follow-up (for data reported thus
far) was 19.4 months. Although full results on OS will not be
available until 2012, preliminary results on PFS, OS and adverse
events have been published as conference abstracts and presenta-
tions.
Karlan 2010 was a randomised, double-blind, placebo-controlled,
phase II study ofAMG386, an anti-angiopoietin peptibody,which
acts to inhibit angiogenesis by interfering with the interaction be-
tween angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor
(Neal 2010). The trial involved 161 women with recurrent ep-
ithelial ovarian cancer (FIGO stage II-IV), or fallopian tube or
primary peritoneal cancer, and was a three-armed comparison of
paclitaxel chemotherapy with a higher versus lower dose of AMG
386, versus placebo. All women received paclitaxel at 80 mg/m2
once weekly QW (QW = three weeks on/one week off ); women
in arm A (n=53) also received AMG 386 at 10 mg/kg QW (higher
dose); women in arm B (n=53) received AMG 386 at 3 mg/kg
QW (lower dose); and women in arm C (n=55) received placebo
QW. All patients had radiographically-documented progression,
as judged by RECIST or CA125 (GCIG (Gynecologic Cancer
InterGroup) criteria), and ≤ 3 anti-cancer therapies (but at least
one platinum-containing regimen). One hundred and fifty-one
(99%) women had a GOG performance status of zero or one.
One hundred and thirty-seven (85%) women had ovarian cancer;
21 (13%) women had primary peritoneal cancer; and three (2%)
women had fallopian tube cancer. The median age was 59 years
(range 27 to 80 years) in arm A, 60 years (28 to 85) in arm B,
and 62 years (38 to 83) in arm C. The primary outcome was PFS;
secondary outcomes included response as per RECIST, CA125
response, safety and pharmacokinetics. The median length of fol-
low-up (for data reported thus far) was 66.1 weeks in arm A, 65.1
weeks in arm B and 64.4 weeks in arm C. Randomisation (and
hence also analysis) was stratified by whether or not women had
previously had disease progression within six months of the last
chemotherapy regimen, and on whether or not they had had prior
anti-VEGF therapy. Preliminary results for PFS, OS and adverse
events have been published as conference abstracts and presenta-
tions.
Ledermann 2009 was a randomised, double-blind, placebo-con-
trolled, phase II trial to assess the effectiveness of BIBF 1120 ver-
sus placebo as a maintenance therapy in women with chemother-
apy-responsive relapsed ovarian cancer (or fallopian tube or pri-
mary peritoneal cancer). Eighty-four women were recruited: 44
were given oral BIBF 1120 at a dose of 250 mg twice daily for a
period of up to nine months; 40 were given placebo. The mean
age of participants was 60 years (range 27 to 76 years). The pri-
mary outcome was PFS at 36 weeks, as confirmed by CT scan
(performed at 12-week intervals). Secondary outcomes included:
time to tumour progression (according to RECIST criteria and
CA125), PFS at three and six months, OS and incidence/intensity
of adverse events at 9 months.
Vergote 2009 was a randomised, double-blind, placebo-controlled
trial of VEGF-Trap versus placebo in 55 women with chemother-
apy-resistant advanced epithelial ovarian cancer. [VEGF-Trap, also
known as aflibercept, is a decoy receptor for VEGF. It is a fusion
protein, combining the constant region of immunoglobulin IgG1
with the ligand-binding domains of VEGF receptors; it thus can
bind to VEGF, preventing it binding to the VEGF-receptors in
the body, and hence inhibiting angiogenesis (Aflibercept 2008)].
Women were only included in the study if they also had recurrent
malignant ascites (a collection of fluid in the abdominal cavity,
which occurs in some women as a result of ovarian cancer). The
primary aim of the study was to see whether VEGF-Trap could
reduce the need for paracentesis (the procedure for draining the
ascitic fluid), which is not one of the pre-specified outcomes of
interest for this review. However, some of the secondary outcomes
for this study are relevant to the scope of this review (e.g. OS,
adverse events and QoL). Thus, we have included this study, but
have only reported and discussed these specific outcomes (i.e. not
the paracentesis-related outcomes). Women in the intervention
arm receivedVEGF-Trap IV, at a dose of 4mg/kg every twoweeks;
those in the control arm received placebo. The median age was
56 years (range 33 to 88 years). Eighty-four per cent of women
had an ECOG Performance Status of one to two. Participants had
tried a median of four prior lines of chemotherapy (range 2 to 11).
All five of these completed RCTs have published summaries of
their methods and main results in abstract form, as presented at
conferences. We have discussed their results below, as they repre-
sent the current best available data. However, any analysis is pro-
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visional, as further details of methods and results are needed.
Excluded studies
Fron the search strategy we identified seven potentially relevant
references, which we later excluded after obtaining the full text,
for the following reasons.
• One study (Tew 2007) was a report of preliminary data
from a phase II, randomised, double-blind trial comparing two
different doses of VEGF-Trap (2 vs 4 mg/kg) in women with
recurrent platinum-resistant epithelial ovarian cancer. As detailed
in the study protocol (found by searching the clinical trials
databases, and included as a supplementary reference), the
outcome data for the two treatment arms will be compared to
historical controls. [The full results will be published later this
year].
• Two references (Burger 2010; Markman 2009) were
narrative review articles, and did not include any completed or
ongoing studies that met our criteria, and which had not already
been identified by our other search methods.
• One reference (Azad 2008) was a conference abstract,
describing a phase I dose-finding study of sorafenib and
bevacizumab for patients with multiple tumour types, and
emphasising the results for the 15 patients with ovarian cancer;
there was no control group.
• Two references were to a single article (Osterweil 2010; two
linked references), which discussed the results of one of the main
included studies (Burger 2010 (GOG-0218)).
• One reference (Sennino 2010) was an article commenting
on another study, which compared the activity of bevacizumab
to an inhibitor of PDGF-beta in mouse-based models of ovarian
cancer.
From our search of the clinical trials databases, we identified six
ongoing trials which, although randomised studies of angiogenesis
inhibitors in ovarian cancer, did not fulfil our inclusion criteria,
and so we excluded them for the following reasons.
• Two studies (NCT00017303; NCT00543049) involved
patients being randomised to different dosage schedules of an
angiogenesis inhibitor (i.e. with no control group).
• In three ongoing studies (NCT00096200; NCT00886691;
NCT01115829) patients were randomised to an angiogenesis
inhibitor with or without another agent (as opposed to standard
therapy with vs without an angiogenesis inhibitor), so that
patients in all trial arms received the angiogenesis inhibitor.
• One ongoing study (NCT01167712) randomised women
to one of two different dosage schedules of cytotoxic
chemotherapy; although patients in both randomisation arms
could also be treated with bevacizumab, the allocation of
bevacizumab was made by patient choice, rather than
randomisation.
Risk of bias in included studies
All five included trials (Burger 2010 (GOG-0218); Karlan 2010;
Ledermann 2009; Perren2010 (ICON7);Vergote 2009) have thus
far been published only as conference abstracts, so we lacked suf-
ficient information to make an accurate assessment of each trial’s
quality. In some cases, we were able to obtain access to the Pow-
erPoint slides or poster from the original conference presentation,
which provided further detail, but obviously still not as much as
would normally appear in a full published paper. Consequently,
all five trials had ’unclear’ risk of bias: only the trial of Burger 2010
(GOG-0218) satisfied one of the criteria that we used to assess risk
of bias. It was ’unclear’ in all six risk of bias items in the other four
trials and in five of the six in the Burger 2010 (GOG-0218) trial,
which assessed a satisfactory proportion of women who had been
randomised, at the end of the trial (see Figure 2; Figure 3). When
these trials are published in full text we will update the review and
make a thorough assessment of risk of bias.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
For dichotomous outcomes, we were unable to estimate a RR if
one or both of the treatment groups experienced no events.
Overall survival (OS)
Chemotherapy + concurrent bevacizumab + maintenance
placebo versus chemotherapy + concurrent and maintenance
placebo
(See Analysis 1.1)
The trial of Burger 2010 (GOG-0218) found no statistically sig-
nificant difference in the risk of death in women who received
concurrent bevacizumab and maintenance placebo in addition to
chemotherapy and those who received concurrent and mainte-
nance placebo in addition to their chemotherapy (HR 1.04, 95%
CI 0.83 to 1.30).
Chemotherapy + concurrent and maintenance bevacizumab
versus chemotherapy +/- placebo
(See Analysis 2.1)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found no statistically significant difference in the
risk of death in women who received concurrent bevacizumab and
maintenance bevacizumab in addition to chemotherapy and those
who received concurrent and maintenance placebo or no further
treatment in addition to their chemotherapy (HR 0.87, 95% CI
0.73 to 1.03). The percentage of the variability in effect estimates
thatwas due toheterogeneity between studies rather than sampling
error (chance) was not important (I2 = 0%).
Chemotherapy + AMG 386 at 10 mg/kg (high dose) versus
chemotherapy + placebo
(See Analysis 3.1)
In the Karlan 2010 trial, women who received high dose AMG
386 in addition to chemotherapy had in excess of a third-less risk
of death compared towomen receiving placebo in addition to their
chemotherapy, but this difference was not statistically significant
(HR 0.60, 95% CI 0.34 to 1.06).
Chemotherapy + AMG 386 at 3 mg/kg (low dose) versus che-
motherapy + placebo
(See Analysis 4.1)
In the Karlan 2010 trial, women who received low dose AMG 386
in addition to chemotherapy had just over a quarter-less risk of
death compared to women receiving placebo in addition to their
chemotherapy, but this difference was not statistically significant
(HR 0.77, 95% CI 0.45 to 1.31).
VEGF-Trap versus placebo
(See Analysis 6.1)
The trial of Vergote 2009 found no statistically significant dif-
ference in the risk of death in women who received VEGF-Trap
compared to those who received placebo (HR 1.02, 95% CI 0.56
to 1.86).
Progression-free survival (PFS)
Chemotherapy + concurrent bevacizumab + maintenance
placebo versus chemotherapy + concurrent and maintenance
placebo
(See Analysis 1.2)
The trial of Burger 2010 (GOG-0218) found no statistically sig-
nificant difference in the risk of disease progression in women
who received concurrent bevacizumab and maintenance placebo
in addition to chemotherapy and those who received concurrent
and maintenance placebo in addition to their chemotherapy, (HR
0.91, 95% CI 0.79 to 1.04).
Chemotherapy + concurrent and maintenance bevacizumab
versus chemotherapy alone +/- placebo
(See Analysis 2.2)
Meta analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
vacizumab and maintenance bevacizumab in addition to chemo-
therapy had significantly lower risk of disease progression (a quar-
ter-less risk) compared to women who received concurrent and
maintenance placebo or no further treatment in addition to their
chemotherapy (HR 0.75, 95% CI 0.68 to 0.83). The percentage
of the variability in effect estimates that was due to heterogeneity
between studies rather than chance was not important (I2 = 0%).
Chemotherapy + AMG 386 at 10 mg/kg (high dose) versus
chemotherapy + placebo
(See Analysis 3.2)
In the Karlan 2010 trial, women who received high dose AMG
386 in addition to chemotherapy had around a quarter-less risk
of disease progression compared to women receiving placebo in
addition to their chemotherapy, but this difference was not statis-
tically significant (HR 0.70, 95% CI 0.44 to 1.10).
Chemotherapy + AMG 386 at 3 mg/kg (low dose) versus che-
motherapy + placebo
(See Analysis 4.2)
In the Karlan 2010 trial, women who received low dose AMG
386 in addition to chemotherapy had in excess of a third-less risk
of disease progression compared to women receiving placebo in
addition to their chemotherapy (HR 0.57, 95% CI 0.36 to 0.91).
Continuous BIBF 1120 versus placebo
(See Analysis 5.1)
In the Ledermann 2009 trial, women who received continuous
BIBF 1120 had nearly a third-less risk of disease progression com-
pared to women receiving placebo (HR 0.68, 95%CI 0.42, 1.09).
This difference was not statistically significant, although the trial
was reported as not being sufficiently powered for a direct compar-
ison of the two interventions. The authors of this trial concluded
that a large phase III trial is needed to confirm the efficacy of this
drug. The trial reported no deaths during treatment at the end of
36 weeks.
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Severe adverse events
Chemotherapy + concurrent bevacizumab + maintenance
placebo versus chemotherapy + concurrent and maintenance
placebo
The trial of Burger 2010 (GOG-0218) reported on severe adverse
events for the above comparison.
Grade ≥ 2 gastrointestinal adverse events
(See Analysis 1.3)
Women who received concurrent bevacizumab and maintenance
placebo in addition to chemotherapy were more than twice as
likely to suffer moderate or severe gastrointestinal adverse events
than those who received concurrent and maintenance placebo in
addition to their chemotherapy (RR 2.11, 95% CI 0.72 to 6.21),
but this was not statistically significant.
Grade ≥ 2 hypertension
(See Analysis 1.4)
Women who received concurrent bevacizumab and maintenance
placebo in addition to chemotherapy were over two times more
likely to suffer moderate or severe hypertension than those who
received concurrent and maintenance placebo in addition to their
chemotherapy (RR 2.25, 95% CI 1.45 to 3.50).
Grade ≥ 3 proteinuria
(See Analysis 1.5)
The trial found no statistically significant difference in the risk
of severe proteinuria in women who received concurrent beva-
cizumab and maintenance placebo in addition to chemotherapy
and those who received concurrent and maintenance placebo in
addition to their chemotherapy (RR 0.99, 95% CI 0.18 to 5.38).
Grade ≥ 2 pain
(See Analysis 1.6)
The trial found no statistically significant difference in the risk of
moderate or severe pain in women who received concurrent beva-
cizumab and maintenance placebo in addition to chemotherapy
and those who received concurrent and maintenance placebo in
addition to their chemotherapy (RR 1.00, 95% CI 0.85 to 1.18).
Grade ≥ 4 neutropenia
(See Analysis 1.7)
The trial found no statistically significant difference in the risk
of severe neutropenia in women who received concurrent beva-
cizumab and maintenance placebo in addition to chemotherapy
and those who received concurrent and maintenance placebo in
addition to their chemotherapy (RR 1.09, 95% CI 0.98 to 1.23)
.
Febrile neutropenia
(See Analysis 1.8)
The trial found no statistically significant difference in the risk
of febrile neutropenia in women who received concurrent beva-
cizumab and maintenance placebo in addition to chemotherapy
and those who received concurrent and maintenance placebo in
addition to their chemotherapy (RR 1.35, 95% CI 0.69 to 2.66).
Venous thromboembolic event
(See Analysis 1.9)
The trial found no statistically significant difference in the risk of
a venous thromboembolic event in women who received concur-
rent bevacizumab and maintenance placebo in addition to che-
motherapy and those who received concurrent and maintenance
placebo in addition to their chemotherapy (RR 0.88, 95%CI 0.50
to 1.54).
Arterial thromboembolic event
(See Analysis 1.10)
The trial found no statistically significant difference in the risk of
an arterial thromboembolic event in women who received con-
current bevacizumab and maintenance placebo in addition to che-
motherapy and those who received concurrent and maintenance
placebo in addition to their chemotherapy (RR 0.66, 95%CI 0.15
to 2.94).
Grade ≥ 3 non-CNS bleeding
(See Analysis 1.11)
The trial found no statistically significant difference in the risk
of severe bleeding outside the central nervous system (CNS) in
women who received concurrent bevacizumab and maintenance
placebo in addition to chemotherapy and those who received con-
current and maintenance placebo in addition to their chemother-
apy (RR 1.32, 95% CI 0.35 to 4.95).
Chemotherapy + concurrent and maintenance bevacizumab
versus chemotherapy +/- placebo
Grade ≥ 2 gastrointestinal adverse events
(See Analysis 2.3)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
vacizumab and maintenance bevacizumab in addition to chemo-
therapy were around two-and-a-half times more likely to suffer
moderate or severe gastrointestinal adverse events than those who
received concurrent and maintenance placebo or no further treat-
ment in addition to their chemotherapy (RR 2.47, 95% CI 1.08
to 5.67). The percentage of the variability in effect estimates that
was due to heterogeneity between studies rather than chance was
not important (I2 = 0%).
Grade ≥ 2 hypertension
(See Analysis 2.4)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
vacizumab and maintenance bevacizumab in addition to chemo-
therapy were over five times more likely to suffer moderate or se-
vere hypertension than those who received concurrent and main-
tenance placebo or no further treatment in addition to their che-
motherapy (RR 5.13, 95% CI 1.91 to 13.82). The percentage of
the variability in effect estimates that was due to heterogeneity
between studies rather than chance may represent considerable
heterogeneity (I2 = 89%).
Grade ≥ 3 proteinuria
(See Analysis 2.5)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
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vacizumab and maintenance bevacizumab in addition to chemo-
therapy were over two-and-a-half times more likely to suffer severe
proteinuria than those who received concurrent and maintenance
placebo or no further treatment in addition to their chemotherapy
(RR 2.90, 95% CI 0.84 to 10.06), but this was not statistically
significant. The percentage of the variability in effect estimates
that was due to heterogeneity between studies rather than chance
was not important (I2 = 0%).
Grade ≥ 2 pain
(See Analysis 2.6)
The trial of Burger 2010 (GOG-0218) found that women who
received concurrent bevacizumab and maintenance placebo in ad-
dition to chemotherapy had a slightly higher risk of moderate or
severe pain than those who received concurrent and maintenance
placebo in addition to their chemotherapy (RR 1.13, 95%CI 0.97
to 1.33), but this was not statistically significant.
Grade ≥ 3 neutropenia
(See Analysis 2.7)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
vacizumab and maintenance bevacizumab in addition to chemo-
therapy had a slightly higher risk of severe neutropenia than those
who received concurrent and maintenance placebo or no further
treatment in addition to their chemotherapy (RR 1.09, 95% CI
0.99 to 1.21), but this approached borderline significance (P =
0.08). The percentage of the variability in effect estimates that was
due to heterogeneity between studies rather than chance was not
important (I2 = 0%).
Febrile neutropenia
(See Analysis 2.8)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found no statistically significant difference in the
risk of febrile neutropenia between women who received concur-
rent bevacizumab and maintenance bevacizumab in addition to
chemotherapy and those who received concurrent and mainte-
nance placebo or no further treatment in addition to their che-
motherapy (RR 1.23, 95% CI 0.76 to 1.98). The percentage of
the variability in effect estimates that was due to heterogeneity
between studies rather than chance was not important (I2 = 0%).
Venous thromboembolic event
(See Analysis 2.9)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found no statistically significant difference in the
risk of a venous thromboembolic event between women who re-
ceived concurrent bevacizumab and maintenance bevacizumab in
addition to chemotherapy and those who received concurrent and
maintenance placebo or no further treatment in addition to their
chemotherapy (RR 1.64, 95% CI 0.76 to 3.56). The percentage
of the variability in effect estimates that was due to heterogeneity
between studies rather than chance may represent substantial het-
erogeneity (I2 = 71%).
Arterial thromboembolic event
(See Analysis 2.10)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found no statistically significant difference in the
risk of an arterial thromboembolic event between women who re-
ceived concurrent bevacizumab and maintenance bevacizumab in
addition to chemotherapy and those who received concurrent and
maintenance placebo or no further treatment in addition to their
chemotherapy (RR 1.40, 95% CI 0.50 to 3.92). The percentage
of the variability in effect estimates that was due to heterogeneity
between studies rather than chance may represent moderate het-
erogeneity (I2 = 42%).
Grade ≥ 3 bleeding
(See Analysis 2.11)
Meta-analysis of two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) found that women who received concurrent be-
vacizumab and maintenance bevacizumab in addition to chemo-
therapy had around three times the risk of severe bleeding than
those who received concurrent and maintenance placebo or no
further treatment in addition to their chemotherapy (RR 2.90,
95% CI 1.10 to 7.62), and this was statistically significant (P =
0.03). The percentage of the variability in effect estimates that was
due to heterogeneity between studies rather than chance was not
important (I2 = 0%).
Thrombocytopenia
(See Analysis 2.12)
The trial of Perren 2010 (ICON7) foundno statistically significant
difference in the risk of severe thrombocytopenia between women
who received concurrent bevacizumab and maintenance placebo
in addition to chemotherapy and those who received concurrent
and maintenance placebo in addition to their chemotherapy (RR
1.75, 95% CI 0.94 to 3.28).
Chemotherapy + AMG 386 at 10 mg/kg (high dose) versus
chemotherapy + placebo
Grade ≥ 3 adverse events
The trial of Karlan 2010 reported on severe adverse events for the
above comparison.
The trial found no statistically significant difference in the risk
of severe bowel perforation, hypertension, neutropenia, venous
and arterial thromboembolic events, proteinuria, cardiac toxicity
events and hemorrhagic events in women who received chemo-
therapy plus high dose AMG 386 and those who received che-
motherapy and placebo. There were relatively few severe adverse
events reported in each arm (this ranged from no events in either
arm for severe hypertension to 6/53 events in the chemotherapy
plus high dose AMG arm and 9/55 in the placebo arm for severe
venous thromboembolic events).
Chemotherapy + AMG 386 at 3 mg/kg (low dose) versus Che-
motherapy + placebo
Grade ≥ 3 adverse events
The trial of Karlan 2010 reported on severe adverse events for the
above comparison.
The comparison of chemotherapy plus low dose AMG 386 versus
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chemotherapy and placebo yielded similar results in terms of severe
adverse events to the comparison of chemotherapy plus high dose
AMG 386 versus chemotherapy and placebo (see above). The
trial of Karlan 2010 found no statistically significant difference in
the risk of severe bowel perforation, hypertension, neutropenia,
venous and arterial thromboembolic events, proteinuria, cardiac
toxicity events and hemorrhagic events in women who received
chemotherapy plus low dose AMG 386 and those who received
chemotherapy and placebo. (The number of events in each arm
ranged from no events for severe hypertension to 6/52 events in
the chemotherapy plus low dose AMG 386 arm and 9/55 in the
placebo arm for severe venous thromboembolic events).
Continuous BIBF 1120 versus placebo
Severe gastrointestinal adverse events
(See Analysis 5.2)
The trial of Ledermann 2009 found no statistically significant dif-
ference in the risk of a severe gastrointestinal adverse event be-
tween women who received continuous BIBF 1120 and women
who received placebo (RR 1.59, 95% CI 0.50 to 5.03).
VEGF-Trap versus placebo
The trial of Vergote 2009 reported on adverse events for the above
comparison.
Fatal gastrointestinal events
(See Analysis 6.2)
The trial found no statistically significant difference in the risk of
fatal gastrointestinal events between women who received VEGF-
Trap and women who received placebo (RR 2.69, 95% CI 0.30
to 24.28).
Other adverse events
The trial has so far only reported other adverse events observed
in patients treated with VEGF-Trap, and where the investigators
believed the events were related to VEGF inhibition (i.e. no com-
parison figures from the control group).
Of those women who received VEGF-Trap, the trialists observed
dysphonia in 20%, hypertension in 16.7%, proteinuria in 10%
and epistaxis in 6.7%.
D I S C U S S I O N
Summary of main results
We found five RCTs comparing angiogenesis inhibitors to either
placebo or standard chemotherapy in women with ovarian can-
cer (Burger 2010 (GOG-0218); Karlan 2010; Ledermann 2009;
Perren 2010 (ICON7); Vergote 2009). All five trials have thus far
been published only in the form of conference abstracts, and so
there are limited data available (even after contacting investiga-
tors for further information). Some of the trials are expected to
be published in full later this year; others are still awaiting longer-
term follow-up data (e.g. for OS).
Burger 2010 (GOG-0218) was a double-blind, placebo-con-
trolled, phase III RCT in 1873 women with newly-diagnosed ep-
ithelial ovarian cancer, primary peritoneal cancer or fallopian tube
cancer. The study assessed the effects of adding bevacizumab, a hu-
manised monoclonal antibody that binds to vascular endothelial
growth factor, to standard paclitaxel/carboplatin chemotherapy,
either concurrently with the chemotherapy, or both concurrently
and continuing after the chemotherapy (maintenance therapy).
The trial found that the addition of concurrent bevacizumab to
standard chemotherapy did not appear to prolong OS (HR 1.04,
95% CI 0.83 to 1.30; P = 0.73) or PFS (HR 0.91, 95% CI 0.79
to 1.04; P = 0.17). However, the women who received concurrent
bevacizumab had more than twice the risk of moderate or severe
hypertension (RR 2.25, 95% CI 1.45 to 3.50).
The addition of concurrent and maintenance bevacizumab to
standard carboplatin/paclitaxel chemotherapy was also assessed in
Perren 2010 (ICON7), an open-label phase III randomised trial
in 1528 women with newly-diagnosed epithelial ovarian cancer,
primary peritoneal cancer or fallopian tube cancer.
Meta-analysis of the two trials (Burger 2010 (GOG-0218); Perren
2010 (ICON7)) assessing 2707 participants, suggested that the
addition of concurrent and maintenance bevacizumab to standard
chemotherapy compared to chemotherapy alone (with or without
placebo) may prolong OS (HR 0.87, 95% CI 0.73 to 1.03; P =
0.10), but this was not statistically significant and longer follow-up
is needed. There was however evidence of a reduction in the risk of
disease progression by a quarter (HR 0.75, 95%CI 0.68 to 0.83; P
< 0.001). Women who received concurrent and maintenance be-
vacizumab had an increased risk of severe gastrointestinal adverse
events (HR 2.47, 95% CI 1.08 to 5.67; P = 0.03), moderate or
severe hypertension (HR 5.13, 95% CI 1.91 to 13.82; P = 0.001)
and severe bleeding (HR 2.90, 95% CI 1.10 to 7.62; P = 0.03)
compared towomenwho received chemotherapy alone. There was
also an increased risk of severe neutropenia in the concurrent and
maintenance bevacizumab group compared to the chemotherapy
alone group (HR 1.09, 95% CI 0.99 to 1.21; P = 0.08) but this
only approached borderline significance.
The main difference between the two trials was that Burger 2010
(GOG-0218) used bevacizumab at a dose of 15 mg/kg, whereas
Perren 2010 (ICON7) used bevacizumab at a dose of 7.5 mg/
kg. Additionally, the trial of Burger 2010 (GOG-0218) was dou-
ble-blind so that patients in the control (chemotherapy only) arm
were given placebo in place of bevacizumab, while the Perren
2010 (ICON7) trial was open-label so that patients in the con-
trol arm did not receive placebo and were aware that they were
not receiving bevacizumab. The lack of blinding in Perren 2010
(ICON7) could potentially have influenced outcomes, in that
knowing which treatment group a patient is in could affect the
patient’s performance, but could also affect the assessment of their
doctors (e.g. in terms of judging progression). In terms of par-
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ticipants, the main difference was that the women in the Burger
2010 (GOG-0218) trial were, in general, more high risk (all had
stage III-IV disease) than those in the Perren 2010 (ICON7) trial
(which included women with high-risk stage I-II disease, as well
as stage III-IV).
Karlan 2010was a double-blind, placebo-controlled, phase IIRCT
ofAMG386, an anti-angiopoietin peptibody,which acts to inhibit
angiogenesis by interfering with the interaction between angiopoi-
etin-1 and angiopoietin-2 with the Tie-2 receptor. The trial in-
volved 161 women with recurrent epithelial ovarian cancer (FIGO
stage II-IV), or fallopian tube or primary peritoneal cancer, and
was a three-armed comparison of paclitaxel chemotherapy with
a higher (10 mg/kg) versus lower (3 mg/kg) dose of AMG 386,
versus placebo. The trial did not find strong evidence that the ad-
dition of high-dose AMG 386 prolonged OS (HR 0.60, 95% CI
0.34 to 1.06; P = 0.08) or PFS (HR 0.70, 95% CI 0.44 to 1.10; P
= 0.12), although there was some degree of improvement in both.
The addition of low-dose AMG 386 did not appear to improve
OS (HR 0.77, 95% CI 0.45 to 1.31; P = 0.34), but there was
some evidence of a reduction in the risk of disease progression by
over a third (HR 0.57, 95% CI 0.36 to 0.91; P = 0.02). The trial
did not find strong evidence of an increased risk of adverse events
associated with either low-dose or high-dose AMG 386.
Ledermann 2009 was a double-blind, placebo-controlled, phase II
RCT of BIBF 1120, a small molecule inhibitor of three receptors
involved in angiogenesis (vascular endothelial growth factor recep-
tor, fibroblast growth factor receptor and platelet-derived growth
factor receptor). The trial involved 84womenwith chemotherapy-
responsive relapsed ovarian, fallopian tube or primary peritoneal
cancer. The trial did not find strong evidence that the addition
of BIBF 1120 either reduced the risk of disease progression (HR
0.68, 95%CI 0.42 to 1.08; P = 0.10) or increased the risk of severe
gastrointestinal adverse events (HR 1.59, 95% CI 0.50 to 5.03).
Vergote 2009 was a double-blind, placebo-controlled, RCT of
VEGF-Trap, a fusion-protein decoy-receptor for vascular endothe-
lial growth factor. The trial involved 55 women with chemother-
apy-resistant advanced epithelial ovarian cancer and recurrent ma-
lignant ascites. The trial found no evidence that VEGF-Trap pro-
longed OS (HR 1.02, 95% CI 0.56 to 1.86; P = 0.94). There was
also no evidence of an increased risk of fatal gastrointestinal events
(HR 2.69, 95% CI 0.30 to 24.28).
Overall, the results of these five RCTs are not sufficient to con-
firm whether or not there is a survival benefit from angiogenesis
inhibitors in the treatment of ovarian cancer.
Twelve ongoing trials were identified which, from the methods
reported thus far, are likely to meet our inclusion criteria when
completed.
• Four studies are of bevacizumab in different settings: as a
first-line therapy (NCT01081262); in platinum-resistant disease
(AURELIA: NCT00976911); and in recurrent disease
(NCT00565851; OCEANS: NCT00434642).
• Three studies are of sorafenib in different settings: as first-
line therapy (Hainsworth 2010); in advanced disease
(NCT00791778); and in platinum-resistant recurrent disease
(NCT01047891).
• One trial is of BIBF 1120 as a first-line therapy
(NCT01015118).
• One trial is of AMG 386, in combination with paclitaxel,
following surgery and platinum-based chemotherapy
(TRINOVA-1: NCT01204749).
• One trial is of pazopanib as a second-line treatment
(NCT00866697).
• One trial is of cediranib in relapsed disease (ICON6:
NCT00532194).
• One trial is of an antibody to PDGF-R-alpha in platinum-
refractory/resistant disease (McGuire 2010).
Overall completeness and applicability of
evidence
Overall, the quality of the evidence was low (GRADE Working
Group) as all trials were at an unclear risk of bias, outcomes were
incompletely documented, and follow-up was insufficient to ad-
equately assess differences in survival that may or may not have
been present. Although we identified five RCTs that met our in-
clusion criteria, none have yet reported their methods and results
in full, and thus they are at an unclear (and potentially high) risk
of bias. When the results of these trials have been published in full
it is likely that the evidence will be upgraded and by the time the
results of the ongoing trials are made available the completeness of
evidence should be very thorough. Only two of the trials used the
same drug (Burger 2010 (GOG-0218); Perren 2010 (ICON7),
both of bevacizumab), while the other three trials examined thee
different agents, in slightly different populations. At least two of
these (Ledermann 2009; Vergote 2009) probably lacked the sta-
tistical power to detect an effect, even if present, due to relatively
small sample sizes. This makes it more difficult to draw general
conclusions about the efficacy of angiogenesis inhibitors in treat-
ing ovarian cancer. Furthermore, we found no good-quality, non-
randomised studies with concurrent comparison groups, making
it difficult to test the robustness of the findings of these varied
trials.
Although we specified QoL as an outcome, none of the five trials
we identified have yet reported QoL data. However, two of them
(Burger 2010 (GOG-0218); Perren2010 (ICON7)) have specified
QoL as a planned outcome, and are expected to report on this
when full data are available.
Angiogenesis inhibitors are not currently in routine use as first-
or second-line treatment of epithelial ovarian, fallopian tube or
primary peritoneal cancers. These trials present limited evidence
that angiogenesis inhibitors (in particular, bevacizumab and AMG
386) might benefit patients with newly-diagnosed high risk/ad-
vanced ovarian cancer or recurrent disease.
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This review summarises the current available evidence, but new
results are being released on a regular basis. For example, as this
review went to press, updated results for one of the trials included
in this review (Perren 2010 (ICON7)) were presented at a confer-
ence, as were preliminary results for an ongoing trial (OCEANS:
NCT00434642). This review will be updated shortly, to incorpo-
rate the newly-available data.
Quality of the evidence
Five trials of four different anti-angiogenic agents, involving a total
of 3701 patients, met the inclusion criteria for the review. These
trials were at an unclear (and potentially high) risk of bias, largely
because of the preliminary nature of the available data. All five tri-
als have been presented at conferences, and thus far published only
as abstracts; the brief nature of these inevitably means that much
of the methodological detail, which is necessary for the assessment
of risk of bias, is absent. None of the trials commented on the
methods used to generate the sequence of random numbers to al-
locate women in the different treatment arms. Neither was it clear
whether there was adequate concealment of allocation from pa-
tients and healthcare professionals involved in the trial. Inadequate
concealment of allocation is often associated with an over-estimate
of the effects of treatment (Moher 1998; Schulz 1995). Thus, the
evidence on OS may be more robust than that for PFS, as blind-
ing of outcome assessors has less potential for influence on death
than disease progression. Four of the trials were described as ’dou-
ble-blind’ (Burger 2010 (GOG-0218); Karlan 2010; Ledermann
2009; Vergote 2009), suggesting that at least the trialists intended
to blind both patients and healthcare professionals to the treat-
ments that were received, although it was not clear whether the
outcome assessor was blinded. One trial (Perren 2010 (ICON7))
was described as ’open-label,’ suggesting that there was no attempt
at blinding.
The trials all reported survival outcomes using a HR, which is the
best statistic to summarise the difference in risk between two treat-
ment groups over the duration of a trial, when there is “censoring”
i.e. the time to death (or disease progression) is unknown for some
women as they were still alive (or disease-free) at the end of the
trial.
Some of the trials have only reported preliminary data, particularly
for outcomes that require longer-term follow-up, such as OS and
PFS.
In the trial of Burger 2010 (GOG-0218), the PFS and preliminary
OS analyses were performed after 1201 (64%) PFS events were
observed and 444 (24%) deaths. More mature OS data (i.e. after
a longer period of follow-up) and QoL data, are still awaited. The
authors reported in detail on selected moderate and severe adverse
events in each trial arm.
In the trial of Perren 2010 (ICON7), the PFS and preliminary
OS analyses were performed after 759 (50%) cases of disease pro-
gression and 241 (16%) deaths. More mature OS data (i.e. after
a longer period of follow-up) and QoL data, are still awaited; up-
datedOS results should be available in 2012. The authors reported
in detail on selected adverse events in each trial arm (both severe
and all grades).
In the Karlan 2010 trial, both PFS and OS data are mature, but it
was not possible to deduce the number of deaths or cases of disease
progression from the Kaplan Meier plots. QoL was not a planned
outcome in the trial. The authors reported in detail on selected
adverse events in each trial arm (both severe and those of special
interest).
In the trial of Ledermann 2009, the PFS analysis was performed
at 36-weeks (as prospectively planned); the authors reported that
there were no deaths on treatment. QoL was not a planned out-
come in the trial. The authors reported briefly on the percentage
of patients in each trial arm who experienced severe adverse events,
but only reported in detail on gastrointestinal toxicities.
In the Vergote 2009 trial, it was not reported how many deaths
had occurred at the time of analysis, as the trial was primarily
concerned with reducing the need for paracentesis in women with
malignant ascites, rather than prolonging survival. The authors
reported on fatal gastrointestinal events separately by trial arm,
but did not report on other adverse events.
It was not clear in four of the five trials how many women were
lost to follow-up, although survival analyses used a HR in all trials
which correctly accounts for censoring. This is more relevant to
severe adverse event outcomes that were reported but it would be
assumed that loss to follow-up would be low for acute toxicity, and
more considerable for survival outcomes and longer-term adverse
events.
Potential biases in the review process
We performed a comprehensive search, including a thorough
search of the grey literature. At least two reviewers sifted and inde-
pendently extracted data for all studies. We restricted the included
studies to RCTs as they provide the strongest level of evidence
available. Hence we have attempted to reduce bias in the review
process.
The greatest threat to the validity of the review is likely to be
the possibility of publication bias, i.e. studies that did not find
angiogenesis inhibitors for the treatment of ovarian cancer to have
been effective may not have been published; we were unable to
assess this possibility.
Agreements and disagreements with other
studies or reviews
Other than the five trials discussed above, we are not aware of
any other completed RCTs of angiogenesis inhibitors compared
to normal chemotherapy and/or placebo in patients with ovar-
ian cancer. However, there have been many phase I and phase II
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studies without control groups. Results of some of the larger non-
controlled phase II studies are discussed below.
Bevacizumab
Bevacizumab is probably the most-studied of the angiogenesis in-
hibitors, and there have been several uncontrolled phase II tri-
als. The studies generally concluded that there was some degree
of disease response (although this is difficult to assess objectively
without a concurrent control group), and several also identified
gastrointestinal adverse events (particularly perforation) and hy-
pertension as important side-effects.
A retrospective analysis of 43 patients from six centres, all of whom
received bevacizumab with chemotherapy for heavily-pretreated
ovarian cancer, found an objective response rate of 40%, with a
median time to progression of 3.8 months (Asmane 2010). Grade
three to four toxicities were reported in 13 (30.2%) women, in-
cluding proteinuria, hypertension, haemorrhage, pelvic abscess
and psychiatric disorders. Three (7.0%) women suffered gastroin-
testinal perforations and six (13.9%) had fistulas.
A phase II study of bevacizumab was conducted in 62 women with
persistent/recurrent ovarian cancer or primary peritoneal cancer
(Burger 2007). Bevacizumab was given at a dose of 15 mg/kg
IV once every 21 days until disease progression or prohibitive
toxicity. Median PFS was 4.7months; median OSwas 17 months.
Twenty-five (40.3%) patients survived progression-free for at least
six months.
Cannistra 2007 was another phase II study of bevacizumab, again
given at 15 mg/kg, once every three weeks. It involved 44 women
with platinum-resistant epithelial ovarian cancer or peritoneal
serous carcinoma, all of whom had experienced disease progres-
sion during, or within three months of discontinuing treatment
with topotecan or liposomal doxorubicin. The overall incidence of
gastrointestinal perforation in this study was 11.4%, but 23.8% in
those women who had three prior chemotherapy regimens (com-
pared to 0% in those who had two prior chemotherapy regimens).
Median PFS was 4.4months (95%CI 3.1 to 5.5months). Median
OS was 10.7 months at the end of the study.
A study of bevacizumab 15 mg/kg, once every three weeks, was
also conducted in 32 patients with recurrent advanced ovarian
cancer, who had failed multiple prior chemotherapeutic regimens
(Monk 2006). Some patients also received cytotoxic chemother-
apy. Median PFS was 5.5 months; median OS was 6.9 months.
Grade three toxicities seen included hypertension, proteinuria and
enterocutaneous fistula.
A phase II study of bevacizumab (10 mg/kg, once every two
weeks) and cytotoxic chemotherapy (metronomic oral cyclophos-
phamide) was conducted in 70women with recurrent ovarian can-
cer (Garcia 2008). Median PFS was 7.2 months; median OS was
16.9 months. There were four episodes of gastrointestinal perfora-
tion or fistula, amongst other adverse events. A very similar study
of bevacizumab and metronomic oral cyclophosphamide was con-
ducted in 38 patients with heavily-pretreated, recurrent ovarian
cancer (Sanchez-Munoz 2010). This trial found a median PFS of
4.5 months, and amedian OS of 10.7 months; there were no cases
of gastrointestinal perforation.
Another study trialled bevacizumab with carboplatin/paclitaxel
chemotherapy (given IV initially, then intraperitoneally) in 40 pa-
tients with ovarian cancer (Krasner 2010). There was no progres-
sive disease during the (unspecified) follow-up period. Significant
grade three to four adverse events included: abdominal pain (5),
fatigue (6), neutropenia (10), thrombocytopenia (5) and nausea
(4).
A phase II study of carboplatin/paclitaxel with bevacizumab as
concurrent and then maintenance therapy in 62 women with ad-
vancedMullerian tumours (73%with ovarian cancer) found a PFS
of 58% at 36-months (Penson 2010). Two gastrointestinal per-
forations and two pulmonary emboli occurred, both during the
chemotherapy phase.
Preliminary data from a phase II study of bevacizumab as concur-
rent (with oxaliplatin and docetaxel cytotoxic chemotherapy) and
then maintenance therapy in 110 women with advanced ovarian,
peritoneal or fallopian tube cancer (Rose 2009) showed one case of
colonic perforation associated with bevacizumab. Common grade
three to four adverse events included neutropenia (39%), leukope-
nia (11%), hypertension (9%) and fatigue (7%).
A phase II study of nab-paclitaxel and bevacizumab in 48 women
with recurrent, platinum-resistant ovarian cancer found a median
PFS of 8.3 months and median OS of 16.5 months (Tillmanns
2010). Bowel obstruction was reported in 3.8% of patients. Other
common toxicities included neutropenia, anaemia, nausea, nose-
bleed, neuropathy and infection.
Given that several trials of angiogenesis inhibitors have reported
gastrointestinal perforations and/or fistulae as adverse events, some
studies have also been conducted to look specifically at this as a
potential sideeffect. A retrospective study of the medical records
of 160 patients with ovarian cancer, who had been treated with
bevacizumab off-protocol at one institution (Diaz 2010), found
that six (4%) developed gastrointestinal perforations.
Another retrospective chart review was conducted of patients with
recurrent ovarian cancer who had been treated in a centre in the
USA, comparing 68 patients who had received bevacizumab (67%
in combination with chemotherapy) to 195 patients who had re-
ceived standard chemotherapy alone (Sfakianos 2009). The study
found that, amongst women treated with bevacizumab (with or
without chemotherapy), five (7.2%) developed a gastrointesti-
nal perforation and/or fistula, compared to 13 (6.5%) women
amongst those treated with chemotherapy alone (RR 1.09, 95%
CI 0.40 to 2.96). The authors therefore concluded that “beva-
cizumab does not significantly increase gastrointestinal toxicity
compared to standard salvage chemotherapy.” However, as this
was not a randomised study, the two groups of women almost
certainly also differed in other ways, and so one must be cautious
about drawing conclusions of comparative safety.
A third retrospective study assessed the incidence of bowel perfo-
ration and hypertension amongst 32 women with advanced ovar-
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ian cancer, who had been treated with one of two dosage regi-
mens of carboplatin, paclitaxel and bevacizumab (Abaid 2010).
The authors reported no cases of bowel perforation and two cases
of “clinically significant” hypertension.
A fourth retrospective study was aimed at assessing the efficacy
and adverse events associated with use of bevacizumab amongst
64 women with recurrent ovarian cancer who had been treated
with bevacizumab plus chemotherapy (Cheng 2009). The authors
reported that fifteen (23.4%) patients had grade three or four
adverse events, and that gastrointestinal perforations occurred in
two (3.1%) patients.
A fifth retrospective study of 51 women with recurrent ovarian
cancer who had received paclitaxel chemotherapy and bi-weekly
bevacizumab, found an overall median PFS of 7months and ame-
dian OS of 12 months (Hurt 2009). Three (5%) patients suffered
bowel perforations.
Other angiogenesis inhibitors
A phase II open-label study of pazopanib (given 800 mg daily,
orally) was conducted in 36 women with recurrent ovarian can-
cer and an elevated CA125, who had previously had a complete
CA125 response to platinum-based chemotherapy (Friedlander
2010). The authors reported that eleven (31%) women had a
CA125 response, and PFS at six months was 17% (95% CI 6%
to 33%).
One phase II study of imatinib (given 400 mg daily, orally), in 35
women with ovarian cancer in second or greater remission, found
that the PFS was not prolonged beyond the historical estimate
(Juretzka 2008); the authors also reported that they found no
association between PDGF-R staining and PFS.
Another phase II trial of daily imatinib was conducted in women
with recurrent ovarian cancer (Alberts 2007), this time limited to
those with tumours expressing one of two targets against which
imatinib acts (c-kit/CD117 or PDGF-R). Although 34 women
were registered for the trial, 15 were ineligible or not evaluable. Of
the 19 women whowere evaluable, two (11%) had tumours which
tested positive for c-kit and 17 (89%) for PDGF-R. However, no
women showed an objective response. Median PFS was 2 months
and median OS was 10 months.
A phase II study of daily sorafenib (in combination with weekly
gemcitabine) in 43 women with recurrent ovarian cancer found
a median time to progression of 5.4 months, and a median OS
of 13.0 months (Welch 2010). Common adverse events reported
included haematologic toxicity, hand-foot syndrome, fatigue, hy-
pokalaemia and diarrhoea.
A phase II study of daily cediranib amongst 47 women with re-
current ovarian cancer found that median PFS was 5.2 months
(Matulonis 2009). In terms of side-effects, grade three hyperten-
sion occurred in 46%, fatigue in 24% and diarrhoea in 13%. The
authors reported no bowel perforations or fistulas.
Previous studies have suggested that hypertension and proteinuria
are common adverse events associatedwith inhibitors of the VEGF
pathway. Thus, one phase II study of cediranib in 31 women with
recurrent epithelial ovarian cancer incorporated detailed monitor-
ing of hypertension and proteinuria (Robinson 2010). The trial
found that 31 (67%) women had developed hypertension by day
three of therapy and 87% by the end of the study. Forty-three per
cent developed grade ≥ 3 hypertension. Fourteen (30%) women
developed proteinuria, in seven of whom it occurred in the first
two weeks of starting therapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Available data suggest an improvement in PFS, if concurrent and
maintenance bevacizumab is added to conventional chemother-
apy, but no significant effect on OS, for patients with ovarian
cancer. Adverse events were more common in the bevacizumab
arm compared to the placebo arm, several significantly so (severe
gastrointestinal events, severe bleeding, and moderate and severe
hypertension). There was no evidence of an increase in either OS
or PFS with the addition of concurrent (but not maintenance) be-
vacizumab to standard chemotherapy, but there was a significant
increase in the risk of moderate and severe hypertension in the
bevacizumab arm.
These results are relatively promising, suggesting that the combi-
nation of concurrent and maintenance bevacizumab may have a
role, in addition to standard debulking surgery and chemother-
apy, in delaying disease progression in women with newly-diag-
nosed ovarian cancer. However, some cautions must be borne in
mind. Firstly, longer-term follow-up data are needed, in order to
see whether the improvement in PFS is accompanied by any sig-
nificant improvement in OS. Secondly, the finding of improved
PFS is based on only two trials, and one would ideally seek further
confirmation. Thirdly, the data have thus far been published only
as conference abstracts, and must be judged as being at high risk of
bias until further details are known. Fourthly, one of the two trials
on which this finding was based was open-label (i.e. no attempt
at blinding), and thus is particularly open to bias in clinician-as-
sessed outcomes such as disease progression. Fifthly, there is also
evidence of increased risks of adverse events with bevacizumab
therapy, particularly of gastrointestinal events, hypertension and
bleeding, in keeping with findings from non-controlled phase II
studies.
Data show little or weak evidence of improvement in OS and PFS
if high-dose AMG 386 is added to chemotherapy. The addition
of low-dose AMG 386 to chemotherapy was associated with a
significant improvement in PFS, but there was no evidence of an
effect on OS. There was no evidence of significant difference in
the toxicities of the two arms. These results are also encouraging,
particularly the lack of evidence for increased risk of adverse events.
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However, there is currently insufficient evidence to support the
routine use of angiogenesis inhibitors alone or in combination
with chemotherapeutic agents in ovarian, fallopian tube or pri-
mary peritoneal cancer. Further research is needed to confirm or
contradict the results available thus far, both in the form of further
data from the existing trials, and other trials of these and other
anti-angiogenic agents.
Implications for research
There is still considerable uncertainty regarding the circumstances
in which angiogenesis inhibitors should be used in treating ovar-
ian cancer, if at all. Given their specific mechanism of action, it
seems likely that any effect would be greater in those patients
with particularly high levels of angiogenesis (e.g. with over-expres-
sion of VEGF). Several of the completed and ongoing trials thus
also include sub-studies, looking at expression of pro-angiogenesis
markers, and their correlation with disease response. In the ongo-
ing quest for patient-specific medicine, the identification of those
patients who are likely to respond to a drug (and perhaps more
importantly, those who are not likely to respond, and thus should
be spared the unnecessary drug and its attendant sideeffects), con-
tinues to be a priority.
The limited current data (as represented by the five included tri-
als) highlight the gaps in knowledge. One is the issue of whether
angiogenesis inhibitors can affect OS as well as PFS; this is largely
a question of longer-term follow-up, and should be answered (at
least in part for bevacizumab) as more data become available from
the existing (e.g. Burger 2010 (GOG-0218) and Perren 2010
(ICON7)) and ongoing trials. We identified four ongoing trials
of bevacizumab, one of which has just released preliminary results
(OCEANS: NCT00434642). Importantly, the fuller reports of
results should include data on QoL outcomes for at least some
studies. Given the growing evidence of the risk of adverse events
associated with at least some angiogenesis inhibitors, both QoL
and OS data will be important information to help clinicians and
patients balance potential risks and benefits.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Burger 2010 (GOG-0218)
Methods Randomised, double-blind, placebo-controlled phase III trial
Participants 1873 women were enrolled from 336 sites (in the US, Canada, South Korea and Japan)
625 patients were treated in arm I (chemotherapy alone), 625 in arm 2 (chemotherapy
+ concurrent bevacizumab) and 623 in arm 3 (chemotherapy + concurrent bevacizumab
+ maintenance bevacizumab) (see Interventions below for details)
All patients had newly diagnosed (confirmed by histology), previously untreated (i.e. no
prior chemotherapy), advanced epithelial ovarian, fallopian tube or primary peritoneal
cancer. All patients were within 1-12 weeks of initial abdominal surgery for staging and
tumour debulking, after which they had stage III optimal (macroscopic residual disease≤
1 cm) or sub-optimal (> 1 cm) disease or stage IV disease All patients had a Gynecologic
Oncology Group (GOG) Performance Status (PS) of 0-2
Patients were excluded if they had a history of significant vascular events, or evidence of
intestinal obstruction requiring parenteral support
The median age in each arm was 60 years (range 25-86 years in arm 1; 24-88 years in
arm 2; 22-89 years in arm 3)
Histology was serous in 1591 (85%) women, endometrioid in 60 (3%), clear-cell in 52
(3%), mucinous in 21 (1%) and 149 (8%) women had other histology
931 (50%) women had GOG performance status 0, 809 (43%) had status 1 and 133
(7%) had status 2
639 (34%) patients had stage III disease with optimal cytoreduction; 752 (40%) patients
had stage III sub-optimal and 482 (26%) had stage IV disease
77 (4%) women had grade 1 disease, 263 (14%) had grade 2, 1277 (68%) had grade 3
disease and grade was not specified in 256 (14%) women
Baseline characteristics were similar between all three study arms
Interventions Patients were randomised to one of three treatment arms (in ratio 1:1:1, stratified by
GOG performance status and by stage/debulking status). Treatment was planned for a
total of 22 cycles, over a period of 15 months (each cycle lasted 21 days, with infusions
being administered on day 1 of the cycle)
Arm 1: paclitaxel/carboplatin chemotherapy for cycles 1-6 [IV paclitaxel 175 mg/m2 +
carboplatin AUC 6 (AUC = area under the curve)] + placebo for cycles 2-22
Arm 2: paclitaxel/carboplatin chemotherapy as per arm 1 + concurrent bevacizumab (15
mg/kg) for cycles 2-6 + placebo for cycles 7-22
Arm 3: paclitaxel/carboplatin chemotherapy as per arm 1 + concurrent bevacizumab (15
mg/kg) for cycles 2-6 + maintenance bevacizumab for cycles 7-22
Outcomes Primary:
• progression-free survival (PFS) (as judged by radiographic, CA125, clinical
criteria or death)
Secondary:
• overall survival (OS)
• safety
• quality of Life
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Burger 2010 (GOG-0218) (Continued)
• correlative laboratory studies
Notes The key protocol amendments were: a) the inclusion of patients with optimally debulked
(macroscopic residual) disease and b) the change of the primary end-point from OS to
PFS (with unblinding to treatment assignment allowed at the time of disease progression)
The median length of follow-up (for the data reported thus far) was 17.4 months (range
0.0-50.7 months)
Analysis for efficacy was by intent-to-treat (ITT) (n = 1873); analysis for safety was by
ITT as of cycle 2 (n = 1816)
The data thus far are from a data lock when events had been observed in 24% of patients
86 (14%) patients in arm 1, 82 (13%) patients in arm 2, and 117 (19%) patients in arm
3, were on treatment at time of analysis
100 (16%) patients in arm 1, 104 (17%) patients in arm 2, and 148 (24%) patients in
arm 3, completed the regimen
There were a range of different reasons for discontinuation of study treatment
In arm 1: 299 (48%) patients had disease progression; 69 (11%) had adverse events, of
which 57 (9%) occurred in cycles 1-6, and12 (2%) occurred in cycles≥ 7; 8 (1%)patients
died; 44 (7%) patients refused treatment; 19 (3%) patients discontinued treatment for
other reasons
In arm 2: 264 (42%) patients had disease progression; 86 (14%) had adverse events,
of which 73 (12%) occurred in cycles 1-6, and 13 (2%) occurred in cycles ≥ 7; 7
(1%) patients died; 55 (9%) patients refused treatment; 27 (4%) patients discontinued
treatment for other reasons
In arm 3: 164 (26%) patients had disease progression; 94 (15%) had adverse events,
of which 59 (9%) occurred in cycles 1-6, and 35 (6%) occurred in cycles ≥ 7; 13
(2%) patients died; 50 (8%) patients refused treatment; 37 (6%) patients discontinued
treatment for other reasons
Median time-to-event data were estimated using the Kaplan-Meier method. The analysis
was stratified by GOG performance status and by stage/debulking status
At the time of analysis, disease progression was judged to have occurred in 423 (67.
7%) patients in arm 1, in 418 (66.9%) patients in arm 2, and in 360 (57.8%) patients
in arm 3. The 95% CI for arm 2 versus arm 1 was 0.76 to 1.04 in the original data
and abstract, but it was not possible to tweak the ln(HR) and SE(ln(HR)) so that the
RevMan estimate corresponded (outcome 1.2, 95% CI 0.79 to 1.04)
The median PFS was 10.3 months in arm 1, 11.2 months in arm 2 and 14.1 months in
arm 3
At the time of analysis, 156 (25%) patients had died in arm 1, 150 (24%) patients had
died in arm 2 and 138 (22%) patients had died in arm 3
The median length of OS was 39.3 months in arm 1, 38.7 months in arm 2 and 39.7
months in arm 3
The 1-year OS rate was 90.6% in arm 1, 90.4% in arm 2 and 91.3% in arm 3
Please note trial results only published in Abstract form
Data from:
1. conference abstract from ASCO 2010 (conference of the American Society of Clinical
Oncology)
2. Powerpoint presentation from ASCO 2010 (supplied by study investigators)
3. conference abstract fromESMO2010 (conference of the European Society ofMedical
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Burger 2010 (GOG-0218) (Continued)
Oncology)
4. poster from ESMO 2010 (available from ESMO 2010 website http://esmo.poster-
submission.com/search/download/9801)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated regimens”. However,
this was a GOG study, so it is likely that
adequate sequence generation was used
Allocation concealment (selection bias) Unclear risk Abstract did not report whether an attempt
was made to conceal the allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported. Study was reported as dou-
ble-blind, but unclear as to whether out-
come assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk % analysed: 1816/1873 (97%) for out-
comes on safety. All patients analysed for
survival outcomes using ITT approach
Selective reporting (reporting bias) Unclear risk No QoL data yet - but this is a common
problem with the preliminary data report-
ing in abstracts, and applies to some of the
other studies as well
Other bias Unclear risk Insufficient information to assess whether
an additional form of bias may have been
present
Karlan 2010
Methods Randomised, double-blind, placebo-controlled phase II trial
Participants 161 women were recruited from 38 sites in 5 countries. All had recurrent epithelial
ovarian (FIGO stage II-IV), fallopian tube or primary peritoneal cancer (confirmed by
histology/cytology)
53 patients were treated in arm 1 (paclitaxel + AMG 386 10 mg/kg), 53 in arm B
(paclitaxel + AMG 386 3 mg/kg) and 55 in arm C (paclitaxel + placebo)
All patients had radiographically documented progression, as judged by RECIST or
CA125 (GCIG criteria), and ≤ 3 anticancer therapies (but at least one platinum-con-
taining regimen). All patients had a GOG performance status of 0 or 1, and adequate
renal and hepatic function
The median age was 59 years (range 27-80 years) in arm A, 60 years (28-85) in arm B
and 62 years (38-83) in arm C
137 (85%) women had ovarian cancer; 21 (13%) women had primary peritoneal cancer;
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Karlan 2010 (Continued)
3 (2%) women had fallopian tube cancer
Histology was serous in 87 (54%) women, endometrioid in 16 (10%), clear cell in 3
(2%), mucinous in 2 (1%), unclassified in 46 (29%) and unavailable in 7 (4%) women
88 (55%) women had GOG performance status 0, 71 (44%) women had status 1, and
2 (1%) women had status 2-3
6 (4%) women had FIGO stage I-II disease, 76 (47%) had stage III, and 41 (25%) had
stage IV; the stage of disease was unknown or unavailable for 38 (24%) women
87 (54%) women had a history of disease progression on or within 6 months of the last
chemotherapy regimen
8 (5%) women had previously been treated with anti-VEGF therapy
145 (90%) women had measurable disease at baseline
61 (38%) women had a history of one prior anticancer therapy; 100 (62%) had a history
of two or more therapies
86 (53%) women had a history of one prior platinum regimen; 75 (47%) had a history
of two or more
12 (8%) women were platinum-refractory at baseline, 63 (39%) were platinum-resistant
(PFI = platinum-free interval < 6 months), 53 (33%) were partially sensitive to platinum
(PFI 6-12 months), and 31 (19%) women were platinum-sensitive (PFI > 12 months);
data were unavailable on platinum sensitivity status for 2 (1%) women
Baseline characteristics were fairly similar between all three study arms
Interventions Patients were stratified, based on whether or not they had had disease progression within
6 months of the last chemotherapy regimen, and on whether or not they had had prior
anti-VEGF therapy. They were then randomised (1:1:1) to one of three arms, until
disease progression, death or unacceptable toxicity (or withdrawn consent)
Arm A: paclitaxel at 80 mg/m2 IV once weekly QW (3 weeks on/1 week off ) plus AMG
386 at 10 mg/kg IV QW
Arm B: paclitaxel at 80 mg/m2 IV QW (3 weeks on/1 week off ) plus AMG 386 at 3
mg/kg IV QW
Arm C: paclitaxel at 80 mg/m2 IV QW (3 weeks on/1 week off ) plus placebo IV QW
Patients in armCwho showed disease progression were allowed to have a period of open-
label therapy with AMG 386 at 10 mg/kg IV weekly
Patients were assessed by CT or MRI scans of the chest, abdomen and pelvis every 8
weeks. CA125 lab values were obtained centrally every 8 weeks and locally as needed
Outcomes Primary:
• PFS (defined as time from randomisation to disease progression per RECIST,
CA125 (GCIG criteria), clinical progression or death)
Secondary:
• response as per RECIST (ORR)
• CA125 response (per GCIG)
• safety
• pharmacokinetics
Notes The median follow-up time was 66.1 weeks in arm A, 65.1 weeks in arm B and 64.4
weeks in arm C
Median PFS was 7.3 months in arm A, 7.4 months in arm B and 5.0 months in arm C
Hazard ratios (HRs) for PFS were obtained using a Cox regression model (stratified by
prior anti-VEGF therapy, and progression within 6 months of the last chemotherapy
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regimen). Comparing the hazard of PFS for arm A (10 mg/kg AMG 386) vs arm C
(placebo), the HR was 0.70 (80% CI 0.52to 0.93; P = 0.113). The HR for arm B (3
mg/kg AMG 386) vs arm C (placebo) was 0.57 (80% CI 0.42 to 0.77; P = 0.016). The
combined HR for Arms A and B (AMG 386) versus arm C (placebo) was 0.64 (80% CI
0.50 to0.82 P = 0.022)
Median OS was 22.5 months for arm A, 20.4 months for arm B and 20.9 months for
arm C
HRs for OS obtained using a Cox regression model were 0.60 (80% CI 0.42 to0.88; P
= 0.081) for arm A vs arm C and 0.77 (80% CI 0.54 to 1.09; P = 0.330) for arm B vs
arm C
The analysis of safety data was restricted to treated patients (52 patients in arm A, 53 in
arm B and 55 in arm C)
Please note trial results only published in abstract form
Data from:
1. conference abstract from ASCO 2010
2. Powerpoint presentation from ASCO 2010 (supplied by study investigators)
3. conference abstract fromESMO 2010. [Please note this was presented as Vergote et al,
but is about the same study, and by the same team, but with a different order of authors]
4. poster from ESMO 2010 (available from ESMO 2010 website http://esmo.poster-
submission.com/search/download/9798). [Again, authors listed in different order to
ASCO 2010, i.e. Vergote et al.]
5. trial protocol at http://www.clinicaltrials.gov/show/NCT00479817
6. conference abstracts of the pharmacokinetic analysis of the trial, by Lu et al., from
ASCO 2010 and ESMO 2010
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported, “Randomised” was used in
abstract but further details were not pro-
vided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported. Study was reported as “dou-
ble-blind”, but unclear as to whether out-
come assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Only limited data presented in abstract/
Powerpoint poster
Other bias Unclear risk Insufficient information to assess whether
an additional form of bias may have been
present
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Ledermann 2009
Methods Randomised, double-blind, placebo-controlled phase II trial
Participants 84 women with chemotherapy-responsive relapsed ovarian cancer were recruited. [i.e. all
women had previously had relapsed ovarian cancer, which had then responded to their
last (at least second-line) chemotherapy, according to GCIG criteria.]
44 women were in the intervention (BIBF 1120) arm and 40 in the placebo arm
The mean age was 60 years (range 27-76 years)
41% of women had had a treatment-free interval before prior chemotherapy of < 6
months; 59% had had an interval of 6-12 months
Interventions BIBF 1120 (250 mg, oral, twice daily, given for up to 9 months)
versus
Placebo
Outcomes Primary:
• PFS Rate at 36 weeks [confirmed by CT assessment, performed at 12-week
intervals]
Secondary:
• time to tumour progression according to RECIST and the tumour marker CA125
• PFS at 3 and 6 months
• survival and Incidence and Intensity of Adverse Events at 9 months
Notes The median duration of treatment was 116 days (range 2-281 days) in the intervention
(BIBF 1120) arm and 101 days (range 2-239 days) in the placebo arm
The PFS rate at 36 weeks was 15.6% (95% CI 3.8 to 27.3%) for the BIBF 1120 arm
and 2.9% (95% CI 0.0 to8.4%) for the placebo arm
The PFS HR was 0.68 (95% CI 0.42 to 1.09)
The median time to progression by RECIST criteria was 4.8 months in the BIBF 1120
arm and 2.8 months in the placebo arm
The fact that only the abstract was available meant the results (including adverse events)
were not very detailed:
grade 3 adverse events occurred in 54% of patients in the BIBF 1120 arm and 25% of
patients in the placebo arm;
grade 4 adverse events occurred in 7% of patients in the BIBF 1120 arm and 3% of
patients in the placebo arm; and
grade 3 gastrointestinal toxicities were seen in 16% of patients in the BIBF 1120 arm
and 10% of patients in the placebo arm
Elevated liver enzymes were noted in 43% of patients in the BIBF 1120 arm and 6.3%
of patients in the placebo arm
Information from:
1. Conference Abstract from ASCO 2009
2. Trial Protocol at http://www.clinicaltrials.gov/show/NCT00710762
Risk of bias
Bias Authors’ judgement Support for judgement
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Ledermann 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not reported: “randomised” was used in
title, but no further details were provided
elsewhere in the abstract
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported. Study was reported as “dou-
ble-blind”, but unclear as to whether out-
come assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Only limited data presented in abstract
Other bias Unclear risk Insufficient information to assess whether
an additional form of bias may have been
present
Perren 2010 (ICON7)
Methods Randomised, two-arm, multi-centre, open-label phase III study
Participants 1528womenwere recruited from263 sites in 7GCIG (GynecologicCancer InterGroup)
groups. 764 women were in each of the study arms (chemotherapy + either bevacizumab
or placebo)
All women had a new, histologically confirmed, diagnosis of EITHER a)High risk FIGO
stage I and IIa epithelial ovarian cancer, with grade 3 or clear cell histology, OR b) FIGO
stage IIb-IV epithelial ovarian cancer OR c) fallopian tube or primary peritoneal cancer
All women had previously had surgical debulking, with the aim of maximal surgical
cytoreduction, and had no plans for further surgical debulking before disease progression.
[Women with inoperable stage III/IV disease were eligible (after biopsy), if no further
surgery was planned]
The median age was 57 years (range 18-81) in the control group, and 57 years (range
24-82) in the bevacizumab group
692 (45%) women had an ECOG performance status of 0, 720 (47%) had status 1 and
88 (6%) had status 2; data on performance status was unknown/unavailable for 28 (2%)
women
1340 (88%) women had epithelial ovarian cancer, 56 (3%) had fallopian tube cancer,
106 (7%) had primary peritoneal cancer and 26 (2%) women had cancer at multiple
sites
Histology was serous in 1054 (69%) women, clear cell in 127 (8%), endometrioid in
117 (8%), mucinous in 34 (2%) and mixed/other in 196 (13%)
97 (6%) women had grade 1 disease, 317 (21%) had grade 2 and 1094 (72%) had grade
3; the grade was unknown for 20 (1%) women
142 (9%) women had FIGO high risk stage I/IIA disease (grade 3 or clear cell histology)
, 315 (21%) had stage IIB-IIIB and 1071 (70%) had stage IIIC/IV disease
1111 (73%) women had optimal surgery (≤ 1 cm residual disease), 387 (25%) women
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had sub-optimal surgery (> 1 cm residual disease) and 30 (2%) women had not had
surgery
Baseline characteristics were similar between the two study arms
Stratification variables
FIGO stage and residuum
1026 (67%) women had stage I-III disease with ≤ 1 cm residual disease, 290 (19%)
women had stage I-III disease with > 1cm residual disease and 212 (14%) women had
either inoperable stage III disease or stage IV
Intent to start chemotherapy
654 (43%) women intended to start chemotherapy ≤4 weeks from surgery; 874 (57%)
women intended to start chemotherapy > 4 weeks from surgery
Interventions Women were randomised in a 1:1 ratio to cytotoxic chemotherapy (carboplatin and
paclitaxel) with or without bevacizumab. Treatment continued until either disease pro-
gression or unacceptable toxicity
Randomisation was stratified on three variables: the stage and extent of debulking (stage
I-III debulked ≤ 1 cm vs stage I-III debulked > 1 cm vs stage IV and inoperable stage
III); the timing of starting the intended treatment (≤ 4 vs≥ 4 weeks after surgery); and
GCIG group
Control arm: carboplatin AUC 6 (AUC = area under the curve) IV over 30-60 mins +
paclitaxel 175 mg/m2 IV over 3 hours on day 1 of cycle Treatment repeats once every 3
weeks for up to 6 cycles
Intervention arm: carboplatin + paclitaxel as in the control arm, plus bevacizumab 7.5
mg/kg IV over 30-90 minutes on the same day Patients may receive the combination of
bevacizumab + chemotherapy for up to 6 cycles, and then continue with bevacizumab
alone (still once every 3 weeks) for up to 12 cycles
Patients were assessed by CT scan at baseline; CT scans were repeated after cycles 3 and
6, then at 9 and 12 months, then every 6 months in years 2 and 3, and then as indicated
in years 4 and 5
Patients had clinical assessments/CA125 measurements at every chemotherapy cycles,
then every 6 weeks during the maintenance phase in year 1, then every 3 months in years
2 and 3, and then every 6 months in years 4 and 5
Outcomes Primary:
• PFS [disease progression defined by RECIST guidelines on radiological, clinical
or symptomatic progression; CA125 elevation alone was not defined as disease
progression]
Secondary:
• OS (results due in 2012)
• response rate
• duration of response
• toxicity
Substudies:
• quality of life
• health economics
• translational (biomarker) research
Notes Themedian length of follow-up (at the time of reporting data thus far) was 19.4 months.
At this point, 2 patients were still on treatment, and there had been 759 events (progres-
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sions or deaths)
For the purposes of the regulatory analysis, PFS censoring was at the time of most recent
CT scan
[An academic analysis was also performed, for which PFS censoring was at the latter of
either the most recent CT scan or the last clinical follow-up. In the interests of simplicity,
we have not reported these results here]
The median length of PFS was 16 months in the placebo group, and 18.3 months in
the intervention (bevacizumab) group (HR 0.79, 95% CI 0.68 to0.91; P = 0.001 - from
log-rank test)
In a preliminary analysis of OS, 130 (17%) women in the placebo arm had died, com-
pared to 111 (15%) women in the bevacizumab arm (HR 0.81, 95% CI 0.63 to1.04; P
= 0.098 - log-rank test)
Data from:
1. conference presentation from ESMO 2010 (at http://www.icon7trial.org)
2. conference abstract from ESMO 2010
3. trial protocol http://www.controlled-trials.com/isrctn/pf/91273375
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported: “randomised” was men-
tioned in abstract and protocol, but no fur-
ther details were provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Open label” trial, so by implication no
blinding attempted
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Only Conference Presentation data avail-
able so far, but no obviously selective re-
porting of outcomes
Other bias Unclear risk Insufficient information to assess whether
an additional form of bias may have been
present
35Angiogenesis inhibitors for the treatment of ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vergote 2009
Methods A randomised, double-blind, placebo-controlled trial
Participants 55 women with advanced ovarian cancer, resistant to chemotherapy (platinum-resistant,
and topotecan-resistant and/or liposomal doxorubicin-resistant)
All women also had symptomatic malignant ascites, for which they needed paracentesis
1-4 times per month
Patients were excluded if they had a shunt (e.g. perito-venous) for management of their
ascites. They were also excluded if they had had prior treatment with an inhibitor of
VEGF or VEGF-R
Interventions Women were randomised to either VEGF-Trap (n = 29, 4 mg/kg IV every 2 weeks), also
known as Aflibercept, or placebo (n=26)
After 60 days, women could cross-over and receive VEGF-Trap in an open-label phase
Outcomes Primary:
• time to repeat paracentesis
Secondary:
• other paracentesis-related parameters
• OS (not mentioned as outcome in protocol, but reported in abstract)
• tolerability
• safety/adverse events
• quality of life (not reported in abstract, but mentioned as outcome in protocol)
• patient-reported outcomes (not reported in abstract, but mentioned as outcome
in protocol)
Notes The main aim of this study was to look at the effect of VEGF-Trap on the need for
paracentesis for malignant ascites (e.g. increasing the length of time until another para-
centesis was needed), and hence these are the main outcomes reported by the trialists.
However, we have only reported and discussed those outcomes which are of relevance to
this specific review, i.e. survival and adverse events
This trial has so far only been presented at a conference (and subsequently published as
an abstract), and hence the data available are currently very limited. The full report is
expected to be published within the next few months
The median age of participants was 56 years (range 33-88 years)
84% of women had ECOG Performance Status of 1-2
Patients had a median of 4 prior lines of chemotherapy (range 2-11)
There was no evidence of a difference between the VEGF-Trap vs placebo groups in
terms of OS (HR 1.023, 95% CI 0.562 to 1.863)
The authors report four fatal gastrointestinal events: three patients in the VEGF-Trap
arm had intestinal perforations, and one patient on placebo developed a fistula, followed
by sepsis
The authors also report the following other adverse events, which were observed amongst
women treated with VEGF-Trap: dysphonia (20%), hypertension (16.7%), proteinuria
(10%), epistaxis (6.7%). [The precise number of women who suffered each adverse event
was unclear]
Date from:
1. conference abstract from ESGO 2009
2. abstract to forthcoming full published report of the study (kindly provided by study
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Vergote 2009 (Continued)
investigators)
3. trial Protocol http://www.clinicaltrials.gov/ct2/show/NCT00327444
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Title and abstract say that allocation was
“randomised,” but details of sequence gen-
eration are not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Protocol, title and abstract all mention that
study was “double-blind”, and patients in
the control arm received placeboPrecise de-
tails of blinding are not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Only limited data presented in abstract
Other bias Unclear risk Insufficient information to assess whether
an additional form of bias may have been
present
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Azad 2008 Not an RCT. This was a phase I dose-finding study of sorafenib and bevacizumab for patients with multiple
tumour types; this report emphasises results for the 15 patients with ovarian cancer
Burger 2010 Comprehensive narrative review of literature on VEGF inhibitors for gynaecologic malignancies, including sum-
mary tables of completed and ongoing trials. Not a systematic review
Markman 2009 A narrative review of the literature on angiogenesis inhibitors in ovarian cancer
NCT00017303 Ongoing randomised phase II study of IM-862 (which has anti-angiogenic action) in patients with resected stage
III ovarian cancer. Study excluded because all patients receive IM-862, randomised to one of three different dosage
schedules (i.e. patients are not randomised to therapy with vs without angiogenesis inhibitor)
NCT00096200 Ongoing randomised phase II study in patients with recurrent ovarian cancer. All patients receive sorafenib; one
group receives sorafenib only, while the other group receives sorafenib plus carboplatin and paclitaxel. Study
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(Continued)
excluded as it does not compare treatment with vs without angiogenesis inhibitor
NCT00543049 Ongoing randomised phase II study in patients with platinum-refractory ovarian cancer. All patients receive
sunitinib; they are randomised to one of two different dosage schedules. Study excluded as it does not compare
treatment with vs without angiogenesis inhibitor
NCT00886691 Ongoing randomised phase II study in patients with recurrent/persistent ovarian cancer, comparing therapy with
bevacizumab alone vs bevacizumab + everolimus (an inhibitor of a serine-threonine kinase). [Thus, the trial is not
comparing therapy with vs without an angiogenesis inhibitor]
NCT01115829 An ongoing randomised phase I/II study of cediranib with vs without olaparib (a PARP-inhibitor, which targets
tumour growth via a different pathway to angiogenesis inhibitors). Study excluded because all patients receive
the angiogenesis inhibitor cediranib (i.e. patients are not randomised to treatment with vs without angiogenesis
inhibitor)
NCT01167712 Ongoing randomised phase III trial of two different dosage schedules of paclitaxel and carboplatin in patients with
Stage II/IV ovarian cancer. Study excluded because, although patients in both randomisation arms may have their
chemotherapy with or without bevacizumab, the decision of whether or not to include bevacizumab is made by
patient choice, rather than randomisation
Osterweil 2010 Not an RCT. Two different references to a single article, reporting and commenting on a conference abstract about
a phase III RCT (Burger 2010 (GOG-0218))
Sennino 2010 Not an RCT. An article commenting on another paper, which compared the activity of bevacizumab to an inhibitor
of PDGF-beta in mouse-based models of ovarian cancer
Tew 2007 Phase II study, involving 162 patients with recurrent platinum-resistant ovarian cancer, randomised to either 2
mg/kg VEGF-Trap or 4 mg/kg VEGF-Trap (i.e. no control group, given only standard therapy and/or placebo)
Characteristics of studies awaiting assessment [ordered by study ID]
Gordon 2010
Methods An adaptive randomised discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumours.
An ongoing, phase II, randomised discontinuation trial, comprising an open-label Lead-In tage (stage 1), and a
double-blinded Randomised stage (stage 2). [The stage 2 results would constitute an RCT, and so would be relevant
to this review]
Participants Patients with advanced solid tumours will be recruited into nine tumour-specific cohorts (breast, gastric/gastro-
oesophageal junction, small cell lung, non-small cell lung, ovarian, pancreatic, hepatocellular, melanoma and prostate
cancer). [Obviously, only the ovarian cancer cohort would be relevant to this review.]
Interventions Stage 1 (open-label, non-randomised): All patients receive XL 184 (an oral inhibitor of multiple tyrosine kinases,
including VEGF-R2, MET and RET) at a dose of 100 mg daily for 12 weeks. Those with a partial or complete
response (as judged by modified RECIST criteria) will continue with daily XL 184 until disease progression. Those
with stable disease will continue to Stage 2 (randomisation)
Stage 2 (double-blind, randomised): patients with stable disease are randomised 1:1 to receive either daily XL184 or
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Gordon 2010 (Continued)
placebo, until disease progression
A ’non-randomised expansion cohort’ is also planned, in which all subjects receive open-label Xl 184 (100 mg daily)
until disease progression
Outcomes Primary:
• stage 1: objective response rate
• stage 2: PFS
Secondary:
• safety and tolerability
• correlation between clinical outcome and factors such as: the pathway dysfunction of disease-related genes,
specific proteins (e.g. MET), or downstream signalling molecules
• pharmacokinetics/pharmacodynamics
Notes This ongoing trial may or may not be suitable for inclusion, depending on whether or not the cohort of patients
with ovarian cancer proceed to stage 2 (i.e. a double-blind, randomised trial of XL184)
The protocol has been published on ClinicalTrials.gov:
http://www.clinicaltrials.gov/ct2/show/NCT00940225
Characteristics of ongoing studies [ordered by study ID]
AURELIA: NCT00976911
Trial name or title AURELIA: a study of Avastin (bevacizumab) added to chemotherapy in patients with platinum-resistant
ovarian cancer
Methods Phase III, randomised, open-label, two-arm, multi-centre study
Participants Women≥ 18 years old with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Interventions Randomisation to chemotherapy (paclitaxel, topotecan and liposomal doxorubicin) with bevacizumab, or
chemotherapy alone
Outcomes Primary:
• PFS
Secondary:
• objective response rate, biological PFS, OS
• quality of life: EORTC, HADS, FOSI
• safety and tolerability: AEs, laboratory parameters, ECOG performance status, vital signs
Starting date October 2009
Contact information Developing drug company: Roche/Genentech
Roche medical information contact: Dr Isabelle Widmer (isabelle.widmer@roche.com)
Notes Protocol online at: http://clinicaltrials.gov/show/NCT00976911
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Hainsworth 2010
Trial name or title Paclitaxel and carboplatin with or without sorafenib in the first-line treatment of patients with ovarian cancer
Methods Phase II, randomised, active control, open-label
Participants Women ≥ 18 years old, with histologically-confirmed stage III or IV epithelial ovarian cancer, who have
undergone cytoreductive surgery, and who do not have residual large volume disease (no tumour nodules >
3 cm in size), bowel involvement or intestinal obstruction
Interventions Randomised to standard chemotherapy (paclitaxel and carboplatin), either with or without sorafenib
Outcomes Primary:
• PFS
Starting date October 2006
Contact information Principal Investigator: John D. Hainsworth, MD, Sarah Cannon Research Institute
tel: 1-877-MY-1-SCRI
asksarah@scresearch.net
jhainsworth@tnonc.com
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT00390611
Also presented as ongoing trial poster/abstract at ASCO 2010
ICON6: NCT00532194
Trial name or title ICON6 - a double-blind, placebo-controlled, three-arm, randomised, multi-centre Gynaecologic Cancer
InterGroup trial of cediranib (AZD2171), in combination with platinum-based chemotherapy and as a single
agentmaintenance therapy, inwomenwith ovarian cancer relapsingmore than 6months following completion
of first line platinum-based treatment
Methods Phase III, double-blind, placebo-controlled, three-arm, randomised, multicentre study
Participants Women ≥ 18 years old, with histologically proven diagnosis of epithelial ovarian carcinoma, fallopian tube
carcinoma, or primary serous peritoneal carcinoma, with proven relapsed disease occurring more than six
months since completion of first-line platinum-based chemotherapy
Interventions Randomisation to one of three different study arms
Arm A (reference): standard platinum-based chemotherapy plus a daily oral placebo tablet for the duration of
the chemotherapy and then for up to 18 months from the time of randomisation, or until protocol defined
disease progression occurs
Arm B (Concurrent cediranib): standard chemotherapy plus daily oral cediranib during chemotherapy only,
and then an oral daily placebo tablet for up to 18 months from the time of randomisation, or until protocol
defined disease progression or toxicity limiting treatment occurs
Arm C (Concurrent and maintenance cediranib): standard chemotherapy plus oral cediranib daily during
chemotherapy and then continued for up to 18 months from the time of randomisation, or until protocol
defined disease progression or toxicity limiting treatment occurs
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ICON6: NCT00532194 (Continued)
Outcomes Primary:
• stage 1: safety
• stage 2: PFS
• stage 3: OS
Secondary:
• stage 1: none
• stage 2: OS and toxicity
• stage 3: PFS, toxicity and QoL
Starting date November 2007
Contact information Prof Jonathan Ledermann, University College London, Cancer Research UK and UCL Cancer Trials Centre,
90 Tottenham Court Road, London W1T 4TJ, United Kingdom
Notes Protocol online at: http://www.controlled-trials.com/mrct/trial/724143
McGuire 2010
Trial name or title Randomised phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived
growth factor receptor-alpha (PDGF-R-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resis-
tant advanced ovarian cancer
Methods Phase II, open-label, randomised controlled trial
Participants Women with platinum-refractory/resistant ovarian cancer from13-15 North American and European centres.
A total of 110 enrolled patients is aimed for; 25 patients had been enrolled at 6 sites as of January 2010
Interventions Randomisation to either arm A or arm B, continuing until disease progression or other withdrawal criteria:
arm A: doxorubicin (40 mg/m2) every 4 weeks + IMC-3G3 (20 mg/kg) every 2 weeks
arm B: doxorubicin (40 mg/m2) every 4 weeks
Patients in arm B may receive IMC-3G3 monotherapy upon disease progression
[IMC-3G3 is an inhibitor of PDGF-R-alpha, another tyrosine-kinase enzyme involved in angiogenesis, and
which is often associated with VEGF-R.]
Outcomes Primary:
• PFS
Secondary:
• OS
• objective response rate
• median duration of response
• adverse events
• IMC-3G3 antibody and pharmacokinetic assessments
Starting date June 2009
Contact information Email: ClinicalTrials@ImClone.com
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McGuire 2010 (Continued)
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT00913835
Also presented as ongoing trial poster/abstract at ASCO 2010
NCT00565851
Trial name or title Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent
ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer
Methods Phase III, randomised, multi-centre study
Participants Women≥ 18 years old, with recurrent ovarian epithelial carcinoma, primary peritoneal carcinoma or fallopian
tube carcinoma
Interventions All patients have surgical cytoreduction if appropriate. Whether or not they have surgery, patients are then
randomised to one of two treatment arms
Arm I: chemotherapy (carboplatin plus either paclitaxel or docetaxel)
Arm II: chemotherapy as per arm I, plus bevacizumab
Outcomes Primary:
• OS
Secondary:
• PFS
• frequency and severity of adverse events
Starting date December 2007
Contact information Study Chair: Robert L Coleman, MD
M.D. Anderson Cancer Center
Email: rcoleman@mdanderson.org
Notes Protocol online at: http://clinicaltrials.gov/show/NCT00565851
NCT00791778
Trial name or title Comparison of Nexavar/placebo as maintenance therapy for patients with advanced ovarian or primary
peritoneal cancer
Methods Phase II, randomised, double-blind, placebo-controlled
Participants Women ≥ 18 years old, with histologically-confirmed FIGO stage III or IV ovarian epithelial cancer or
primary peritoneal cancer, who have achieved a complete clinical response after tumour debulking surgery
and only one regimen of standard platinum and taxane-based chemotherapy
Interventions Randomisation to sorafenib (also known as Nexavar) or placebo
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NCT00791778 (Continued)
Outcomes Primary:
• PFS, based on time to CT-documented relapse
Secondary:
• time to first pathologic CA125 serum levels
• OS
• ovarian cancer symptoms response
• general health status
Starting date November 2008
Contact information Bayer Healthcare Pharmaceuticals Inc.
Email: medical.information@bayer.co.uk
Web: www.bayerscheringpharma.co.uk
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT00791778
NCT00866697
Trial name or title Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or
primary peritoneal cancer
Methods Phase III, randomised, double-blind
Participants Women ≥ 18 years old, with non-bulky FIGO Stage II-IV ovarian, fallopian tube or primary peritoneal
cancer that has not progressed after completing first-line chemotherapy
Interventions Randomisation to Ppazopanib monotherapy or placebo
Outcomes Primary:
• PFS
Secondary:
• OS
• Safety and tolerability at 1 year
• 3-year PFS
• PFS by GCIG criteria
• QoL
Starting date March 2009
Contact information US GSK Clinical Trials Call Center: 877-379-3718
Email: info@clinicaltrialsforgsk.com
Notes Protocol online at: http://clinicaltrials.gov/show/NCT00866697
Extension trial in Asian women: NCT01227928 [see supplementary reference for this study]
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NCT01015118
Trial name or title BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first-line treatment of ovarian cancer
Methods Phase III, randomised, double-blind, placebo-controlled
Participants Women ≥ 18 years old, with advanced epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
Interventions Patients randomised to one of two arms, and followedup for 41 months
Arm I: paclitaxel and carboplatin chemotherapy, plus oral BIBF 1120
Arm II: paclitaxel and carboplatin chemotherapy, plus oral placebo
Outcomes Primary:
• PFS
Secondary:
• PFS according to Response Evaluation Criteria In Solid Tumors 1.1 criteria
• OS
• Time to tumour marker progression
• Objective response
• Incidence and intensity of adverse events
• Changes in safety laboratory parameters
Starting date November 2009
Contact information Boehringer Ingelheim Call Centre: 1-800 243-0127
Email: clintriage.rdg@boehringer-ingelheim.com
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT01015118
NCT01047891
Trial name or title Efficacy and safety study of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian
cancer (TRIAS 2009)
Methods Phase II, randomised, placebo-controlled, double-blind
Participants Women ≥ 18 years old, with platinum-resistant recurrent ovarian cancer
Interventions Randomisation to IV topotecan and oral sorafenib, or IV topotecan and oral placebo
Outcomes Primary:
• PFS
Secondary:
• OS
• Response rate
• Duration of response
• Time to progression
• Safety and tolerability
• QoL
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NCT01047891 (Continued)
Starting date January 2010
Contact information Jalid Sehouli, Professor
Tel: +49 (0) 30 450 564043
Email: sehouli@aol.com
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT01047891
NCT01081262
Trial name or title Carboplatin and paclitaxel or oxaliplatin and capecitabine, with or without bevacizumab, as first-line therapy
in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian
cancer or fallopian tube cancer
Methods Phase III, randomised, open-label, multi-centre study
Participants Women ≥ 18 years old, with newly-diagnosed stage II-IV or recurrent stage I mucinous epithelial ovarian or
fallopian tube cancer
Interventions Patients are first stratified according to disease status, then randomised to one of four treatment arms
Arm I: IV carboplatin and paclitaxel every 3 weeks for 6 courses
Arm II: single dose IV oxaliplatin and daily oral capecitabine for 2 weeks; repeat every 3 weeks for 6 courses
Arm III: as for arm I, plus bevacizumab, then continue bevacizumab every 3 weeks for another 12 courses
Arm IV: as for arm II, plus bevacizumab as for arm III
Outcomes Primary Outcome:
• OS
Secondary Outcomes:
• PFS
• Response rate
• Toxicity
• Quality-of-life
• Financial costs vs clinical benefits
Starting date January 2010
Contact information Principal Investigator: Martin E. Gore, MD. Royal Marsden NHS Foundation Trust
Principal Investigator: David M Gershenson, MD. M.D. Anderson Cancer Center
Notes Protocol online at: http://www.clinicaltrials.gov/show/NCT01081262
45Angiogenesis inhibitors for the treatment of ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OCEANS: NCT00434642
Trial name or title A study of carboplatin and gemcitabine plus bevacizumab in patients with ovary, peritoneal, or fallopian tube
carcinoma (OCEANS)
Methods Phase III, randomised, double-blind (subject, investigator), placebo-contolled, parallel assignment, multicen-
tre study
Participants Women ≥ 18 years old, with documented ovarian, primary peritoneal or fallopian tube carcinoma that has
recurred, with measurable disease, and no prior chemotherapy in the recurrent setting
Interventions Randomisation to experimental arm (bevacizumab + carboplatin + gemcitabine) or placebo comparator
(placebo + carboplatin + gemcitabine)
Outcomes Primary:
• PFS
Secondary:
• Objective response and duration of response
• OS
• Incidence of gastrointestinal perforation (GIP)
• Characterisation of the safety of bevacizumab in combination with carboplatin and gemcitabine
• Incidence of all adverse events
Starting date April 2007
Contact information Developing drug company: Roche/Genentech
Roche medical information contact: Dr Isabelle Widmer (isabelle.widmer@roche.com)
Notes Protocol online at: http://clinicaltrials.gov/show/NCT00434642
TRINOVA-1: NCT01204749
Trial name or title TRINOVA-1: a study of AMG 386 or placebo, in combination with weekly paclitaxel chemotherapy, as
treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer
Methods Phase III, Randomised, double-blind, placebo-controlled, multicentre study
Participants Women ≥ 18 years old with a histo/cytological diagnosis of invasive epithelial ovarian cancer, primary
peritoneal cancer or fallopian tube cancer, for which they have undergone surgery and a platinum-based
chemotherapy
Interventions Randomisation to weekly IV infusions of either paclitaxel and placebo (control arm), or paclitaxel and AMG
386
Outcomes Primary:
• PFS
Secondary:
• Incidence of the occurrence of anti-AMG 386 antibody formation
• Patient-reported health related quality of life (HRQOL) and ovarian cancer related symptoms using
the functional assessment of cancer therapy - ovary questionnaire (FACT-O)
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TRINOVA-1: NCT01204749 (Continued)
• OS
• Objective Response Rate
• Duration of Response
• CA125 response rate per Gynecologic Cancer Intergroup (GCIG) and change in CA125
• Incidence of adverse events and significant laboratory abnormalities
• Pharmacokinetics of AMG 386 (Cmax and Cmin)
• Overall health status using EuroQOL (EQ5D)
Starting date October 2010
Contact information MD, Study Director, Amgen
Amgen Call Center
tel: 866-572-6436
Notes Protocol online at: http://clinicaltrials.gov/show/NCT01204749
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D A T A A N D A N A L Y S E S
Comparison 1. Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and main-
tenance placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
2 Progression-free survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
3 Grade ≥2 gastrointestinal
adverse events
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
4 Grade ≥2 hypertension 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
5 Grade ≥3 proteinuria 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
6 Grade ≥2 pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
7 Grade ≥4 neutropenia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
8 Febrile neutropenia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
9 Venous thromboembolic event 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
10 Arterial thromboembolic event 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
11 Non-CNS bleeding (grade ≥3) 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 2. Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 2 2707 Hazard Ratio (Random, 95% CI) 0.87 [0.73, 1.03]
1.1 Concurrent BEV (15
mg/kg)
1 1209 Hazard Ratio (Random, 95% CI) 0.92 [0.73, 1.15]
1.2 Concurrent BEV (7.5
mg/kg)
1 1498 Hazard Ratio (Random, 95% CI) 0.81 [0.63, 1.04]
2 Progression-free survival 2 2707 Hazard Ratio (Random, 95% CI) 0.75 [0.68, 0.83]
2.1 Concurrent BEV (15
mg/kg)
1 1209 Hazard Ratio (Random, 95% CI) 0.72 [0.63, 0.82]
2.2 Concurrent BEV (7.5
mg/kg)
1 1498 Hazard Ratio (Random, 95% CI) 0.79 [0.68, 0.91]
3 Severe gastrointestinal adverse
events
2 2407 Risk Ratio (IV, Random, 95% CI) 2.47 [1.08, 5.67]
3.1 Grade ≥2 GI events 1 909 Risk Ratio (IV, Random, 95% CI) 1.98 [0.67, 5.87]
3.2 Grade ≥3 GI perforation 1 1498 Risk Ratio (IV, Random, 95% CI) 3.37 [0.93, 12.19]
4 Grade ≥2 hypertension 2 2407 Risk Ratio (IV, Random, 95% CI) 5.13 [1.91, 13.82]
5 Grade ≥3 proteinuria 2 2407 Risk Ratio (IV, Random, 95% CI) 2.90 [0.84, 10.06]
6 Grade ≥2 pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
7 Severe neutropenia 2 2407 Risk Ratio (IV, Random, 95% CI) 1.09 [0.99, 1.21]
7.1 Grade ≥3 1 1498 Risk Ratio (IV, Random, 95% CI) 1.09 [0.86, 1.38]
7.2 Grade ≥4 1 909 Risk Ratio (IV, Random, 95% CI) 1.10 [0.98, 1.23]
8 Febrile neutropenia 2 2407 Risk Ratio (IV, Random, 95% CI) 1.23 [0.76, 1.98]
48Angiogenesis inhibitors for the treatment of ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8.1 All grades 1 909 Risk Ratio (IV, Random, 95% CI) 1.17 [0.59, 2.34]
8.2 Grade ≥3 1 1498 Risk Ratio (IV, Random, 95% CI) 1.28 [0.66, 2.50]
9 Venous thromboembolic event 2 2407 Risk Ratio (IV, Random, 95% CI) 1.64 [0.76, 3.56]
9.1 All grades 1 909 Risk Ratio (IV, Random, 95% CI) 1.13 [0.66, 1.93]
9.2 Grade ≥3 1 1498 Risk Ratio (IV, Random, 95% CI) 2.49 [1.32, 4.70]
10 Arterial thromboembolic event 2 2407 Risk Ratio (IV, Random, 95% CI) 1.40 [0.50, 3.92]
10.1 All grades 1 909 Risk Ratio (IV, Random, 95% CI) 0.66 [0.15, 2.93]
10.2 Grade ≥3 1 1498 Risk Ratio (IV, Random, 95% CI) 2.02 [0.95, 4.29]
11 Grade ≥3 bleeding 2 2407 Risk Ratio (IV, Random, 95% CI) 2.90 [1.10, 7.62]
11.1 Non-CNS bleeding
(grade ≥3)
1 909 Risk Ratio (IV, Random, 95% CI) 2.15 [0.62, 7.47]
11.2 Grade ≥3 bleeding 1 1498 Risk Ratio (IV, Random, 95% CI) 4.55 [0.99, 20.98]
12 Thrombocytopenia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 3. Chemo + AMG 386 at 10 mg/kg versus chemo + placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
2 Progression-free survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
Comparison 4. Chemo + AMG 386 at 3 mg/kg versus chemo + placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
2 Progression-free survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
Comparison 5. Continuous BIBF 1120 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression-free survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
2 Severe gastrointestinal adverse
events
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
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Comparison 6. VEGF-Trap versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 1 Hazard Ratio (Random, 95% CI) Subtotals only
2 Fatal gastrointestinal events 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 1 Overall survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 1 Overall survival
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 607 601 0.04 (0.115) 1.04 [ 0.83, 1.30 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours concurrent Bev Favours placebo
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Analysis 1.2. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 2 Progression-free survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 2 Progression-free survival
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 607 601 -0.097 (0.07) 0.91 [ 0.79, 1.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours concurrent Bev Favours placebo
Analysis 1.3. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 3 Grade ≥2 gastrointestinal adverse events.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 3 Grade ≥2 gastrointestinal adverse events
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 17/607 4/301 2.11 [ 0.72, 6.21 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 17 (Chemo+concurrent Bev), 4 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours concurrent Bev Favours placebo
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Analysis 1.4. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 4 Grade ≥2 hypertension.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 4 Grade ≥2 hypertension
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 100/607 22/301 2.25 [ 1.45, 3.50 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 100 (Chemo+concurrent Bev), 22 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours concurrent Bev Favours placebo
Analysis 1.5. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 5 Grade ≥3 proteinuria.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 5 Grade ≥3 proteinuria
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 4/607 2/301 0.99 [ 0.18, 5.38 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Chemo+concurrent Bev), 2 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.6. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 6 Grade ≥2 pain.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 6 Grade ≥2 pain
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 252/607 125/301 1.00 [ 0.85, 1.18 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 252 (Chemo+concurrent Bev), 125 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.7. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 7 Grade ≥4 neutropenia.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 7 Grade ≥4 neutropenia
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 384/607 174/301 1.09 [ 0.98, 1.23 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 384 (Chemo+concurrent Bev), 174 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.8. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 8 Febrile neutropenia.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 8 Febrile neutropenia
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 30/607 11/301 1.35 [ 0.69, 2.66 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 30 (Chemo+concurrent Bev), 11 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.9. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 9 Venous thromboembolic event.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 9 Venous thromboembolic event
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 32/607 18/301 0.88 [ 0.50, 1.54 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 32 (Chemo+concurrent Bev), 18 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.10. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 10 Arterial thromboembolic event.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 10 Arterial thromboembolic event
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 4/607 3/301 0.66 [ 0.15, 2.94 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.11. Comparison 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo +
concurrent and maintenance placebo, Outcome 11 Non-CNS bleeding (grade ≥3).
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 1 Chemo + concurrent bevacizumab + maintenance placebo versus chemo + concurrent and maintenance placebo
Outcome: 11 Non-CNS bleeding (grade ≥3)
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 8/607 3/301 1.32 [ 0.35, 4.95 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 2.1. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 1 Overall survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 1 Overall survival
Study or subgroup
Chemo+conc
BEV+Maint
BEV Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Concurrent BEV (15 mg/kg)
Burger 2010 (GOG-0218) 608 601 -0.088 (0.117) 54.5 % 0.92 [ 0.73, 1.15 ]
Subtotal (95% CI) 608 601 54.5 % 0.92 [ 0.73, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Concurrent BEV (7.5 mg/kg)
Perren 2010 (ICON7) 745 753 -0.21 (0.128) 45.5 % 0.81 [ 0.63, 1.04 ]
Subtotal (95% CI) 745 753 45.5 % 0.81 [ 0.63, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 1353 1354 100.0 % 0.87 [ 0.73, 1.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.2. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 2 Progression-free survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 2 Progression-free survival
Study or subgroup
Chemo+conc
BEV+Maint
BEV Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Concurrent BEV (15 mg/kg)
Burger 2010 (GOG-0218) 608 601 -0.33 (0.07) 52.8 % 0.72 [ 0.63, 0.82 ]
Subtotal (95% CI) 608 601 52.8 % 0.72 [ 0.63, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.71 (P < 0.00001)
2 Concurrent BEV (7.5 mg/kg)
Perren 2010 (ICON7) 745 753 -0.24 (0.074) 47.2 % 0.79 [ 0.68, 0.91 ]
Subtotal (95% CI) 745 753 47.2 % 0.79 [ 0.68, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Total (95% CI) 1353 1354 100.0 % 0.75 [ 0.68, 0.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 5.65 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
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Analysis 2.3. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 3 Severe gastrointestinal adverse events.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 3 Severe gastrointestinal adverse events
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Grade ≥2 GI events
Burger 2010 (GOG-0218) 16/608 4/301 58.3 % 1.98 [ 0.67, 5.87 ]
Subtotal (95% CI) 608 301 58.3 % 1.98 [ 0.67, 5.87 ]
Total events: 16 (Chemo+concurrent Bev), 4 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Grade ≥3 GI perforation
Perren 2010 (ICON7) 10/745 3/753 41.7 % 3.37 [ 0.93, 12.19 ]
Subtotal (95% CI) 745 753 41.7 % 3.37 [ 0.93, 12.19 ]
Total events: 10 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
Total (95% CI) 1353 1054 100.0 % 2.47 [ 1.08, 5.67 ]
Total events: 26 (Chemo+concurrent Bev), 7 (Chemo+placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 2.4. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 4 Grade ≥2 hypertension.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 4 Grade ≥2 hypertension
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 139/608 22/301 51.0 % 3.13 [ 2.04, 4.80 ]
Perren 2010 (ICON7) 136/745 16/753 49.0 % 8.59 [ 5.17, 14.28 ]
Total (95% CI) 1353 1054 100.0 % 5.13 [ 1.91, 13.82 ]
Total events: 275 (Chemo+concurrent Bev), 38 (Chemo+placebo)
Heterogeneity: Tau2 = 0.45; Chi2 = 8.89, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 5 Grade ≥3 proteinuria.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 5 Grade ≥3 proteinuria
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 10/608 2/301 67.7 % 2.48 [ 0.55, 11.23 ]
Perren 2010 (ICON7) 4/745 1/753 32.3 % 4.04 [ 0.45, 36.09 ]
Total (95% CI) 1353 1054 100.0 % 2.90 [ 0.84, 10.06 ]
Total events: 14 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 6 Grade ≥2 pain.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 6 Grade ≥2 pain
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Burger 2010 (GOG-0218) 286/608 125/301 1.13 [ 0.97, 1.33 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 286 (Chemo+concurrent Bev), 125 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 2.7. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 7 Severe neutropenia.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 7 Severe neutropenia
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Grade ≥3
Perren 2010 (ICON7) 123/745 114/753 19.2 % 1.09 [ 0.86, 1.38 ]
Subtotal (95% CI) 745 753 19.2 % 1.09 [ 0.86, 1.38 ]
Total events: 123 (Chemo+concurrent Bev), 114 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Grade ≥4
Burger 2010 (GOG-0218) 385/608 174/301 80.8 % 1.10 [ 0.98, 1.23 ]
Subtotal (95% CI) 608 301 80.8 % 1.10 [ 0.98, 1.23 ]
Total events: 385 (Chemo+concurrent Bev), 174 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 1353 1054 100.0 % 1.09 [ 0.99, 1.21 ]
Total events: 508 (Chemo+concurrent Bev), 288 (Chemo+placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 2.8. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 8 Febrile neutropenia.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 8 Febrile neutropenia
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 All grades
Burger 2010 (GOG-0218) 26/608 11/301 48.4 % 1.17 [ 0.59, 2.34 ]
Subtotal (95% CI) 608 301 48.4 % 1.17 [ 0.59, 2.34 ]
Total events: 26 (Chemo+concurrent Bev), 11 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
2 Grade ≥3
Perren 2010 (ICON7) 19/745 15/753 51.6 % 1.28 [ 0.66, 2.50 ]
Subtotal (95% CI) 745 753 51.6 % 1.28 [ 0.66, 2.50 ]
Total events: 19 (Chemo+concurrent Bev), 15 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 1353 1054 100.0 % 1.23 [ 0.76, 1.98 ]
Total events: 45 (Chemo+concurrent Bev), 26 (Chemo+placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
0.2 0.5 1 2 5
Favours conc+maint BEV Favours placebo
62Angiogenesis inhibitors for the treatment of ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.9. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo,
Outcome 9 Venous thromboembolic event.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 9 Venous thromboembolic event
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 All grades
Burger 2010 (GOG-0218) 41/608 18/301 52.4 % 1.13 [ 0.66, 1.93 ]
Subtotal (95% CI) 608 301 52.4 % 1.13 [ 0.66, 1.93 ]
Total events: 41 (Chemo+concurrent Bev), 18 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Grade ≥3
Perren 2010 (ICON7) 32/745 13/753 47.6 % 2.49 [ 1.32, 4.70 ]
Subtotal (95% CI) 745 753 47.6 % 2.49 [ 1.32, 4.70 ]
Total events: 32 (Chemo+concurrent Bev), 13 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
Total (95% CI) 1353 1054 100.0 % 1.64 [ 0.76, 3.56 ]
Total events: 73 (Chemo+concurrent Bev), 31 (Chemo+placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 3.47, df = 1 (P = 0.06), I2 =71%
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Analysis 2.10. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/-
placebo, Outcome 10 Arterial thromboembolic event.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 10 Arterial thromboembolic event
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 All grades
Burger 2010 (GOG-0218) 4/608 3/301 32.8 % 0.66 [ 0.15, 2.93 ]
Subtotal (95% CI) 608 301 32.8 % 0.66 [ 0.15, 2.93 ]
Total events: 4 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Grade ≥3
Perren 2010 (ICON7) 20/745 10/753 67.2 % 2.02 [ 0.95, 4.29 ]
Subtotal (95% CI) 745 753 67.2 % 2.02 [ 0.95, 4.29 ]
Total events: 20 (Chemo+concurrent Bev), 10 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
Total (95% CI) 1353 1054 100.0 % 1.40 [ 0.50, 3.92 ]
Total events: 24 (Chemo+concurrent Bev), 13 (Chemo+placebo)
Heterogeneity: Tau2 = 0.26; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 1.73, df = 1 (P = 0.19), I2 =42%
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Analysis 2.11. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/-
placebo, Outcome 11 Grade ≥3 bleeding.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 11 Grade ≥3 bleeding
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Non-CNS bleeding (grade ≥3)
Burger 2010 (GOG-0218) 13/608 3/301 60.0 % 2.15 [ 0.62, 7.47 ]
Subtotal (95% CI) 608 301 60.0 % 2.15 [ 0.62, 7.47 ]
Total events: 13 (Chemo+concurrent Bev), 3 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
2 Grade ≥3 bleeding
Perren 2010 (ICON7) 9/745 2/753 40.0 % 4.55 [ 0.99, 20.98 ]
Subtotal (95% CI) 745 753 40.0 % 4.55 [ 0.99, 20.98 ]
Total events: 9 (Chemo+concurrent Bev), 2 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Total (95% CI) 1353 1054 100.0 % 2.90 [ 1.10, 7.62 ]
Total events: 22 (Chemo+concurrent Bev), 5 (Chemo+placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.46), I2 =0.0%
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Analysis 2.12. Comparison 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/-
placebo, Outcome 12 Thrombocytopenia.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 2 Chemo + concurrent and maintenance bevacizumab versus chemo +/- placebo
Outcome: 12 Thrombocytopenia
Study or subgroup
Chemo+concurrent
Bev Chemo+placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Perren 2010 (ICON7) 26/745 15/753 1.75 [ 0.94, 3.28 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 26 (Chemo+concurrent Bev), 15 (Chemo+placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 3.1. Comparison 3 Chemo + AMG 386 at 10 mg/kg versus chemo + placebo, Outcome 1 Overall
survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 3 Chemo + AMG 386 at 10 mg/kg versus chemo + placebo
Outcome: 1 Overall survival
Study or subgroup
Chemo+AMG
at 10 mg/kg Chemo+ placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Karlan 2010 53 55 -0.51 (0.29) 0.60 [ 0.34, 1.06 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 3.2. Comparison 3 Chemo + AMG 386 at 10 mg/kg versus chemo + placebo, Outcome 2
Progression-free survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 3 Chemo + AMG 386 at 10 mg/kg versus chemo + placebo
Outcome: 2 Progression-free survival
Study or subgroup
Chemo+AMG
at 10 mg/kg Chemo+ placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Karlan 2010 53 55 -0.36 (0.23) 0.70 [ 0.44, 1.10 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.1. Comparison 4 Chemo + AMG 386 at 3 mg/kg versus chemo + placebo, Outcome 1 Overall
survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 4 Chemo + AMG 386 at 3 mg/kg versus chemo + placebo
Outcome: 1 Overall survival
Study or subgroup
Chemo+AMG
at 3 mg/kg Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Karlan 2010 53 55 -0.26 (0.27) 0.77 [ 0.45, 1.31 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.2. Comparison 4 Chemo + AMG 386 at 3 mg/kg versus chemo + placebo, Outcome 2
Progression-free survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 4 Chemo + AMG 386 at 3 mg/kg versus chemo + placebo
Outcome: 2 Progression-free survival
Study or subgroup
Chemo+AMG
at 3 mg/kg Chemo+placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Karlan 2010 53 55 -0.56 (0.24) 0.57 [ 0.36, 0.91 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours AMG 386 Favours placebo
Analysis 5.1. Comparison 5 Continuous BIBF 1120 versus placebo, Outcome 1 Progression-free survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 5 Continuous BIBF 1120 versus placebo
Outcome: 1 Progression-free survival
Study or subgroup
Continuous
BIBF 1120 Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ledermann 2009 44 40 -0.39 (0.243) 0.68 [ 0.42, 1.09 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours BIBF 1120 Favours placebo
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Analysis 5.2. Comparison 5 Continuous BIBF 1120 versus placebo, Outcome 2 Severe gastrointestinal
adverse events.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 5 Continuous BIBF 1120 versus placebo
Outcome: 2 Severe gastrointestinal adverse events
Study or subgroup
Continuous
BIBF 1120 Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ledermann 2009 7/44 4/40 1.59 [ 0.50, 5.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (Continuous BIBF 1120), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours BIBF 1120 Favours placebo
Analysis 6.1. Comparison 6 VEGF-Trap versus placebo, Outcome 1 Overall survival.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 6 VEGF-Trap versus placebo
Outcome: 1 Overall survival
Study or subgroup VEGF-Trap Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Vergote 2009 29 26 0.0227 (0.306) 1.02 [ 0.56, 1.86 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours VEGF-Trap Favours placebo
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Analysis 6.2. Comparison 6 VEGF-Trap versus placebo, Outcome 2 Fatal gastrointestinal events.
Review: Angiogenesis inhibitors for the treatment of ovarian cancer
Comparison: 6 VEGF-Trap versus placebo
Outcome: 2 Fatal gastrointestinal events
Study or subgroup VEGF-Trap Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Vergote 2009 3/29 1/26 2.69 [ 0.30, 24.28 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (VEGF-Trap), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.02 0.1 1 10 50
Favours VEGF-Trap Favours placebo
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE Ovid 1990 to October week 3, 2010
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. (animals not (humans and animals)).sh.
11. 9 not 10
12. ovar*.mp.
13. (cancer* or carcinoma* or neoplasm* or tumor* or tumour* or malignan*).mp.
14. 12 and 13
15. exp Ovarian Neoplasms/
16. 14 or 15
17. exp Angiogenesis Inhibitors/
18. exp Vascular Endothelial Growth Factors/
19. vascular endothelial growth factor*.mp.
20. (angiogenesis adj5 inhibit*).mp.
21. VEGF.mp.
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22. (VEGFR or VEGF-R).mp.
23. exp Antibodies, Monoclonal/
24. monoclonal antibodies.mp.
25. (bevacizumab or avastin).mp.
26. (VEGF-Trap or aflibercept or AVE0005).mp.
27. exp Protein-Tyrosine Kinases/
28. (tyrosine kinase adj5 inhibit*).mp.
29. (sorafenib or nexavar or BAY 43-0006 or NSC724772).mp.
30. (cediranib or AZD2171 or recentin).mp.
31. (sunitinib or SU11248).mp.
32. (pazopanib or GW-786034).mp.
33. BIBF 1120.mp.
34. (imatinib mesylate or ST 1571 or gleevec).mp.
35. AEE788.mp.
36. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
37. 11 and 16 and 36
key: pt=publication type, ab=abstract, fs=floating subheading, mp=title, original title, abstract, name of substance word, subject heading
word, sh=medical subject heading
Appendix 2. EMBASE search strategy
EMBASE Ovid 1990 to 2010, week 43
1. exp Controlled Clinical Trial/
2. randomized.ab.
3. placebo.ab.
4. dt.fs.
5. randomly.ab.
6. trial.ab.
7. groups.ab.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animal not (human and animal)).sh.
10. 8 not 9
11. (ovar* and (cancer* or carcinoma* or neoplas* or tumor* or tumour* or malignan*)).mp.
12. exp Ovary Tumor/
13. 11 or 12
14. exp Angiogenesis Inhibitor/
15. exp Vasculotropin/
16. vascular endothelial growth factor*.mp.
17. (angiogenesis adj5 inhibit*).mp.
18. VEGF.mp.
19. (VEGFR or VEGF-R).mp.
20. exp Monoclonal Antibody/
21. monoclonal antibodies.mp.
22. (bevacizumab or avastin).mp.
23. (VEGF-Trap or aflibercept or AVE0005).mp.
24. exp Protein Tyrosine Kinase/
25. (tyrosine kinase adj5 inhibit*).mp.
26. (sorafenib or nexavar or Bay 43-0006 or NSC724772).mp.
27. (cediranib or AZD2171 or recentin).mp.
28. (sunitinib or SU11248).mp.
29. (pazopanib or GW-786034).mp.
30. BIBF 1120.mp.
71Angiogenesis inhibitors for the treatment of ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
31. (imatinib mesylate or ST 1571 or gleevec).mp.
32. AEE788.mp.
33. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 10 and 13 and 33
key: mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name,
ab=abstract, sh=subject heading, fs=floating subheading
Appendix 3. CENTRAL search strategy
CENTRAL Issue 10, November 2010
1. ovar* and (cancer* or carcinoma* or neoplasm* or tumor* or tumour* or malignan*)
2. MeSH descriptor Ovarian Neoplasms explode all trees
3. (#1 OR #2)
4. MeSH descriptor Angiogenesis Inhibitors explode all trees
5. MeSH descriptor Vascular Endothelial Growth Factors explode all trees
6. vascular endothelial growth factor*
7. angiogenesis near/5 inhibit*
8. VEGF
9. VEGFR or VEGF-R
10. MeSH descriptor Antibodies, Monoclonal explode all trees
11. monoclonal antibodies
12. bevacizumab or avastin
13. VEGF-Trap or aflibercept or AVE0005
14. MeSH descriptor Protein-Tyrosine Kinases explode all trees
15. tyrosine kinase near/5 inhibit*
16. sorafenib or nexavar or BAY 43-0006 or NSC724772
17. cediranib or AZD2171 or recentin
18. sunitinib or SU11248
19. pazopanib or GW-786034
20. BIBF 1120
21. imatinib mesylate or ST 1571 or gleevec
22. AEE788
23. (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #
19 OR #20 OR #21 OR #22)
24. #3 and #23
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by JM and KG, with significant input from HD, AB and SN. SK and JM had the initial concept for the title
and approved the final version of the protocol. KG, IM and JM analysed the results of the searches and contacted regulatory bodies,
pharmaceutical companies and authors/investigators of relevant completed and ongoing trials for further information. KG, IM, JM
and AB wrote the review.
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D E C L A R A T I O N S O F I N T E R E S T
None
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR CCRCD, UK.
JM is a Walport Clinical Lecturer, 50% academic component is funded by NIHR CCRCD
• Macmillan Cancer Supoort, UK.
JM is a subspecialist trainee in gynaecological oncology. This 50% clinical post is funded by a grant from Macmillan Cancer Support.
• Department of Health, UK.
NHS Cochrane Collaboration programme Grant Scheme CPG-506
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
How the intervention might work
In the Background section of the protocol, we wrote:
“AZD2171 (RecentinT M Astra Zeneca) is a small molecule inhibitor of VEGF-R that has demonstrated benefit in preclinical studies
(Wedge 2005).”
AZD2171 has been more commonly referred to in the literature as “cediranib,” and so this alternative name is also listed and used in
the review.
Also in the Background section of the protocol, we wrote:
“Pazopanib is a potent selective receptor tyrosine kinase inhibitor of VEGF-R, PDGF-R (platelet derived growth factor receptor) and
c-kit that blocks tumour growth and inhibits angiogenesis. It has shown biological activity in patients with CA125-positive recurrent
ovarian cancer after primary platinum-based therapy and enrolment continues in this study (Friedlander 2007).”
The study described in Friedlander 2007 has now finished, and the full results have been published. The phrase “and enrolment
continues in this study” has therefore been omitted in the review, and the reference has been updated to Friedlander 2010.
Also in the Background section of the protocol, we wrote:
“BIBF 1120 is an oral, small molecule, triple angiokinase inhibitor, targeting VEGF-R, FGF-R (fibroblast growth factor receptor) and
PDGF-R. A recent phase II study has evaluated its use in maintenance of post-relapse remission in patients who responded to second,
third or fourth line chemotherapy. Results from this study are expected later this year at ASCO 2009.”
The results of this study have now been presented in conference/abstract form (Ledermann 2009), and are discussed in detail in the
Included studies section). The phrase “Results from this study are expected later this year at ASCO 2009” has therefore been omitted
in the review, and the updated reference inserted.
Also in the Background section of the protocol, we wrote, regarding sorafenib:
“Activity has been demonstrated against ovarian cancer in early clinical trials for pre-treated relapsed disease (Siu 2006) and its role in
first-line treatment for ovarian cancer is under evaluation (NCT00390611 2006).”
A report of this still-ongoing trial has since appeared as a conference abstract, and so the reference has been updated accordingly, to
Hainsworth 2010.
Also in the Background section of the protocol, we wrote:
“Another VEGF-R tyrosine kinase inhibitor, cediranib (AZD2171), is being trialed as a therapy in RCTs for relapsed ovarian cancer
(ICON6 - 2007; ISRCTN68510403 - 2007).”
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This sentence duplicated information and references given earlier in the same section, and so was omitted from the review.
Quality of life (QoL)
QoL was not reported in any of the abstracts and data has not yet been made available, so the following sections in the protocol which
discussed the handling of data for continuous outcomes were removed as they were unnecessary:
“Data extraction and management
• For continuous outcomes (e.g. QoL measures), we will extract the final value and standard deviation of the outcome of interest
and the number of patients assessed at endpoint in each treatment arm at the end of follow-up, in order to estimate the mean
difference between treatment arms and its standard error.
Measures of treatment effect
• For continuous outcomes, we will use the mean difference between treatment arms if all trials measured the outcome on the
same scale, otherwise standardised mean differences will be used.
Data synthesis
If sufficient, clinically similar studies are available, their results will be pooled in meta-analyses.
• For continuous outcomes, the mean differences between the treatment arms at the end of follow-up will be pooled if all trials
measured the outcome on the same scale, otherwise standardised mean differences will be pooled”.
We identified only five included trials, therefore we were unable to assess reporting biases using funnel plots or adequately carry out
sensitivity analyses. The following sections of the protocol were therefore removed:
“Assessment of reporting biases
Funnel plots corresponding to meta-analysis of the primary outcome will be examined to assess the potential for small study effects
such as publication bias. If these plots suggest that treatment effects may not be sampled from a symmetric distribution, as assumed by
the random-effects model, further meta-analyses will be performed using fixed-effect models.
Sensitivity analysis
Sensitivity analyses will be performed excluding (i) studies at high risk of bias and (ii) using unadjusted results”.
We did not indirectly compare treatment groups so we removed reference to Bucher 1997 in the main text of the review:
“Data synthesis
If sufficient data are available, indirect comparisons, using themethods of Bucher 1997 will be used to compare competing interventions
that have not been compared directly with each other.”
I N D E X T E R M S
Medical Subject Headings (MeSH)
Angiogenesis Inhibitors [adverse effects; ∗therapeutic use]; Antibodies, Monoclonal [adverse effects; therapeutic use]; Antibodies, Mon-
oclonal, Humanized; Antineoplastic Agents [therapeutic use]; Bevacizumab; Indoles [therapeutic use]; Neovascularization, Pathologic
[∗drug therapy]; Ovarian Neoplasms [∗blood supply; drug therapy]; Paclitaxel [therapeutic use]; Recombinant Fusion Proteins [adverse
effects; therapeutic use]; Survival Analysis
MeSH check words
Female; Humans
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